|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
ISO |
Artesunate results in decreased expression of ACTA2 mRNA; Artesunate results in decreased expression of ACTA2 protein Artesunate inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein] Deferoxamine inhibits the reaction [Artesunate results in decreased expression of ACTA2 mRNA] |
CTD |
PMID:30551460 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
affects localization |
ISO |
artesunate affects the localization of AIFM1 protein |
CTD |
PMID:24704559 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
artesunate binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atg12 |
autophagy related 12 |
increases expression |
ISO |
Artesunate results in increased expression of ATG12 mRNA |
CTD |
PMID:30551460 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atg3 |
autophagy related 3 |
increases expression |
ISO |
Artesunate results in increased expression of ATG3 mRNA |
CTD |
PMID:30551460 |
|
NCBI chr11:55,624,928...55,653,212
Ensembl chr11:55,624,917...55,653,224
|
|
G |
Atg5 |
autophagy related 5 |
increases expression |
ISO |
Artesunate results in increased expression of ATG5 mRNA |
CTD |
PMID:30551460 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
[1,2-Dimethylhydrazine co-treated with artesunate] results in increased expression of BAX protein Artesunate results in increased expression of BAX protein |
CTD |
PMID:24704559 PMID:29031619 PMID:33002460 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
[1,2-Dimethylhydrazine co-treated with artesunate] results in decreased expression of BCL2 protein 3-methyladenine inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; acadesine promotes the reaction [Artesunate results in decreased expression of BCL2 protein]; Acetylcysteine inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; dorsomorphin inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; Sirolimus promotes the reaction [Artesunate results in decreased expression of BCL2 protein] |
CTD |
PMID:24704559 PMID:29031619 PMID:33002460 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bst1 |
bone marrow stromal cell antigen 1 |
increases response to substance |
ISO |
BST1 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr14:67,253,706...67,270,203
Ensembl chr14:67,252,998...67,270,180
|
|
G |
Casp3 |
caspase 3 |
increases activity increases cleavage multiple interactions |
ISO |
artesunate results in increased activity of CASP3 protein Artesunate results in increased cleavage of CASP3 protein 3-methyladenine inhibits the reaction [Artesunate results in increased cleavage of CASP3 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Artesunate results in increased cleavage of CASP3 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of CASP3 protein] |
CTD |
PMID:19513562 PMID:24704559 PMID:33002460 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
affects expression |
ISO |
artesunate affects the expression of CASP9 protein |
CTD |
PMID:24704559 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases response to substance increases expression |
ISO |
CAT protein results in decreased susceptibility to artesunate artesunate results in increased expression of CAT protein |
CTD |
PMID:19513562 PMID:20144594 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cct2 |
chaperonin containing TCP1 subunit 2 |
decreases response to substance |
ISO |
CCT2 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 7:52,692,725...52,705,478
Ensembl chr 7:52,692,725...52,706,944
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions increases phosphorylation |
ISO |
APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of CHEK1 protein] |
CTD |
PMID:31664825 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions increases phosphorylation |
ISO |
APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:31664825 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Clip4 |
CAP-GLY domain containing linker protein family, member 4 |
increases response to substance |
ISO |
CLIP4 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 6:23,616,280...23,697,625
Ensembl chr 6:23,616,281...23,677,874
|
|
G |
Coq8a |
coenzyme Q8A |
decreases response to substance |
ISO |
COQ8A mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr13:91,904,731...91,933,588
Ensembl chr13:91,904,739...91,931,431
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of CTNNB1 protein] |
CTD |
PMID:29031619 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Dbh |
dopamine beta-hydroxylase |
increases response to substance |
ISO |
DBH mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248
|
|
G |
Des |
desmin |
multiple interactions decreases expression |
ISO |
Deferoxamine inhibits the reaction [Artesunate results in decreased expression of DES mRNA] Artesunate results in decreased expression of DES mRNA; Artesunate results in decreased expression of DES protein |
CTD |
PMID:30551460 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
artesunate binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
artesunate results in increased expression of FAS protein |
CTD |
PMID:19513562 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Flna |
filamin A |
increases response to substance |
ISO |
FLNA mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr X:152,007,758...152,034,266
Ensembl chr X:152,007,758...152,031,052
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression multiple interactions |
ISO |
Artesunate results in decreased expression of FN1 mRNA; Artesunate results in decreased expression of FN1 protein Deferoxamine inhibits the reaction [Artesunate results in decreased expression of FN1 mRNA] |
CTD |
PMID:30551460 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Artesunate results in decreased expression of FTH1 mRNA] Artesunate results in decreased expression of FTH1 mRNA; Artesunate results in decreased expression of FTH1 protein |
CTD |
PMID:30551460 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Fzd7 |
frizzled class receptor 7 |
increases response to substance |
ISO |
FZD7 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 9:60,931,433...60,934,252
Ensembl chr 9:60,930,875...60,935,781
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
affects response to substance decreases response to substance |
ISO |
GCLC mRNA affects the susceptibility to artesunate GCLC mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
decreases response to substance |
ISO |
GCLM mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
decreases activity multiple interactions |
ISO |
Artesunate results in decreased activity of GPX4 protein Artesunate inhibits the reaction [Carbon Tetrachloride results in increased expression of GPX4 protein] |
CTD |
PMID:30551460 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gstm4 |
glutathione S-transferase mu 4 |
affects response to substance |
ISO |
GSTM4 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 2:195,667,940...195,685,315
Ensembl chr 2:195,680,004...195,685,323
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
decreases expression |
ISO |
artesunate results in decreased expression of GSTP1 protein |
CTD |
PMID:19513562 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Gstt2 |
glutathione S-transferase theta 2 |
affects response to substance |
ISO |
GSTT2 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Gstz1 |
glutathione S-transferase zeta 1 |
affects response to substance |
ISO |
GSTZ1 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr 6:106,794,594...106,805,284
Ensembl chr 6:106,794,074...106,805,284
|
|
G |
H2ax |
H2A.X variant histone |
increases phosphorylation multiple interactions |
ISO |
Artesunate results in increased phosphorylation of H2AX protein APOBEC3C protein promotes the reaction [Artesunate results in increased phosphorylation of H2AX protein] |
CTD |
PMID:31664825 |
|
NCBI chr 8:44,671,927...44,673,257
Ensembl chr 8:44,671,786...44,673,239
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Artesunate inhibits the reaction [Ethanol results in increased expression of IL1B protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL1B mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL1B protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
Artesunate inhibits the reaction [Ethanol results in increased expression of IL6 protein]; Artesunate inhibits the reaction [Glucose results in increased expression of IL6 mRNA]; Artesunate inhibits the reaction [Glucose results in increased secretion of IL6 protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itgb1 |
integrin subunit beta 1 |
increases response to substance |
ISO |
ITGB1 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation |
ISO |
3-methyladenine inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; acadesine promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; Acetylcysteine inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; dorsomorphin inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; Sirolimus promotes the reaction [Artesunate results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:33002460 |
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mgst3 |
microsomal glutathione S-transferase 3 |
affects response to substance |
ISO |
MGST3 mRNA affects the susceptibility to artesunate |
CTD |
PMID:15796179 |
|
NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MKI67 protein] |
CTD |
PMID:29031619 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression |
EXP ISO |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of MMP9 protein] Artesunate results in decreased expression of MMP9 mRNA Chloroquine inhibits the reaction [Artesunate results in decreased expression of MMP9 mRNA] |
CTD |
PMID:29031619 PMID:30551460 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
artesunate inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:27474069 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
decreases response to substance |
ISO |
MTHFD2 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions decreases phosphorylation |
ISO |
acadesine promotes the reaction [Artesunate results in decreased phosphorylation of MTOR protein]; Acetylcysteine inhibits the reaction [Artesunate results in decreased phosphorylation of MTOR protein]; dorsomorphin inhibits the reaction [Artesunate results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:33002460 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
artesunate inhibits the reaction [Glucose results in increased expression of MYD88 protein] |
CTD |
PMID:30031708 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Naca |
nascent polypeptide associated complex subunit alpha |
decreases response to substance |
ISO |
NACA mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 7:468,862...481,992
Ensembl chr 7:469,723...481,992
|
|
G |
Nckap1 |
NCK-associated protein 1 |
increases response to substance |
ISO |
NCKAP1 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 3:65,417,450...65,491,769
Ensembl chr 3:65,417,453...65,492,217
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
decreases expression multiple interactions |
ISO |
Artesunate results in decreased expression of NCOA4 mRNA; Artesunate results in decreased expression of NCOA4 protein Chloroquine inhibits the reaction [Artesunate results in decreased expression of NCOA4 mRNA] |
CTD |
PMID:30551460 |
|
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
affects localization |
ISO |
artesunate affects the localization of NFE2L2 protein |
CTD |
PMID:26340163 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
EXP |
artesunate inhibits the reaction [Glucose results in increased expression of NLRP3 protein] |
CTD |
PMID:30031708 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Artesunate results in increased cleavage of PARP1 protein 3-methyladenine inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; acadesine promotes the reaction [Artesunate results in increased cleavage of PARP1 protein]; Acetylcysteine inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; dorsomorphin inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; Sirolimus promotes the reaction [Artesunate results in increased cleavage of PARP1 protein] |
CTD |
PMID:24704559 PMID:33002460 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of PCNA protein] |
CTD |
PMID:29031619 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
artesunate binds to and results in increased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[Carbon Tetrachloride results in increased susceptibility to Artesunate] which results in increased expression of PTGS2 mRNA; [Carbon Tetrachloride results in increased susceptibility to Artesunate] which results in increased expression of PTGS2 protein |
CTD |
PMID:30551460 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
artesunate inhibits the reaction [Ethanol results in increased expression of RELA protein]; artesunate inhibits the reaction [Glucose results in increased phosphorylation of RELA protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rpa2 |
replication protein A2 |
increases phosphorylation |
ISO |
Artesunate results in increased phosphorylation of RPA2 protein |
CTD |
PMID:31664825 |
|
NCBI chr 5:144,976,789...144,989,445
Ensembl chr 5:144,976,748...144,987,350
|
|
G |
Rpl41 |
ribosomal protein L41 |
decreases response to substance |
ISO |
RPL41 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 7:977,885...978,965
|
|
G |
Rpl6 |
ribosomal protein L6 |
decreases response to substance |
ISO |
RPL6 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr12:35,347,493...35,352,011
Ensembl chr12:35,347,497...35,351,921
|
|
G |
Rpl7 |
ribosomal protein L7 |
decreases response to substance |
ISO |
RPL7 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 5:3,217,184...3,220,192
|
|
G |
Rps12 |
ribosomal protein S12 |
decreases response to substance |
ISO |
RPS12 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps15a |
ribosomal protein S15a |
decreases response to substance |
ISO |
RPS15A mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 1:172,420,151...172,427,021
Ensembl chr 1:172,419,761...172,426,995
|
|
G |
Rps6 |
ribosomal protein S6 |
decreases response to substance |
ISO |
RPS6 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602 Ensembl chr 5:101,371,136...101,374,602
|
|
G |
Slc25a19 |
solute carrier family 25 member 19 |
decreases response to substance |
ISO |
SLC25A19 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr10:100,853,554...100,867,517
Ensembl chr10:100,847,168...100,867,447
|
|
G |
Sp1 |
Sp1 transcription factor |
decreases expression |
ISO |
artesunate results in decreased expression of SP1 protein |
CTD |
PMID:19513562 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Artesunate results in decreased expression of SQSTM1 protein] Artesunate results in decreased expression of SQSTM1 mRNA; Artesunate results in decreased expression of SQSTM1 protein |
CTD |
PMID:30551460 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srsf2 |
serine and arginine rich splicing factor 2 |
decreases response to substance |
ISO |
SRSF2 mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr10:102,052,158...102,055,365
Ensembl chr10:102,052,314...102,055,338
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions increases expression |
ISO |
Chloroquine inhibits the reaction [Artesunate results in increased expression of TIMP1 mRNA] |
CTD |
PMID:30551460 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
artesunate inhibits the reaction [Glucose results in increased expression of TLR4 protein] |
CTD |
PMID:30031708 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
EXP |
artesunate inhibits the reaction [Ethanol results in increased expression of TNF protein]; artesunate inhibits the reaction [Glucose results in increased expression of TNF mRNA]; artesunate inhibits the reaction [Glucose results in increased secretion of TNF protein] |
CTD |
PMID:27474069 PMID:30031708 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
increases expression multiple interactions |
ISO |
Artesunate results in increased expression of TP53 protein Artesunate inhibits the reaction [TPT1 protein binds to TP53 protein] |
CTD |
PMID:33259807 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpt1 |
tumor protein, translationally-controlled 1 |
affects response to substance multiple interactions |
ISO |
TPT1 protein affects the susceptibility to artesunate Artesunate binds to and results in decreased expression of TPT1 protein; Artesunate inhibits the reaction [TPT1 protein binds to TP53 protein] |
CTD |
PMID:15878303 PMID:33259807 |
|
NCBI chr15:51,156,728...51,159,629
Ensembl chr15:51,146,154...51,159,625
|
|
G |
Tufm |
Tu translation elongation factor, mitochondrial |
decreases response to substance |
ISO |
TUFM mRNA results in decreased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr 1:181,073,788...181,077,395
Ensembl chr 1:181,073,788...181,077,395
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions increases phosphorylation |
ISO |
acadesine promotes the reaction [Artesunate results in increased phosphorylation of ULK1 protein]; Acetylcysteine inhibits the reaction [Artesunate results in increased phosphorylation of ULK1 protein]; dorsomorphin inhibits the reaction [Artesunate results in increased phosphorylation of ULK1 protein] |
CTD |
PMID:33002460 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
artesunate inhibits the reaction [1,2-Dimethylhydrazine results in increased expression of VEGFA protein] |
CTD |
PMID:29031619 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Yy1 |
YY1 transcription factor |
decreases expression |
ISO |
artesunate results in decreased expression of YY1 protein |
CTD |
PMID:19513562 |
|
NCBI chr 6:127,706,739...127,731,907
Ensembl chr 6:127,707,596...127,732,747
|
|
G |
Zbtb4 |
zinc finger and BTB domain containing 4 |
increases response to substance |
ISO |
ZBTB4 mRNA results in increased susceptibility to artesunate |
CTD |
PMID:20144594 |
|
NCBI chr10:54,480,698...54,501,492
Ensembl chr10:54,485,071...54,501,492
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity affects response to substance |
ISO |
benazepril results in decreased activity of ACE protein ACE gene polymorphism affects the susceptibility to benazepril |
CTD |
PMID:8359184 PMID:11007831 PMID:12652327 PMID:12848919 PMID:15498266 PMID:15555355 PMID:15788353 PMID:15793787 More...
|
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
affects response to substance increases response to substance multiple interactions |
ISO |
ACE2 gene SNP affects the susceptibility to benazepril ACE2 gene SNP results in increased susceptibility to benazepril [AGT gene polymorphism co-treated with ACE2 gene polymorphism] affects the susceptibility to benazepril |
CTD |
PMID:20559404 PMID:21449848 PMID:27121444 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
[irbesartan co-treated with benazepril] results in decreased expression of ACTA2 protein; benazepril inhibits the reaction [Doxorubicin results in increased expression of ACTA2 mRNA] |
CTD |
PMID:15149348 PMID:20493835 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects response to substance |
ISO |
ADRB2 protein polymorphism affects the susceptibility to benazepril |
CTD |
PMID:15554460 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
decreases expression |
EXP |
benazepril results in decreased expression of AGER mRNA; benazepril results in decreased expression of AGER protein |
CTD |
PMID:19018797 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
decreases expression affects response to substance multiple interactions |
ISO EXP |
benazepril results in decreased expression of AGT protein; benazepril results in decreased expression of AGT protein modified form AGT gene SNP affects the susceptibility to benazepril benazepril inhibits the reaction [Doxorubicin results in increased expression of AGT protein modified form]; benazepril inhibits the reaction [Particulate Matter results in increased expression of AGT protein modified form]; benazepril inhibits the reaction [Streptozocin results in increased expression of AGT protein modified form] [AGT gene polymorphism co-treated with ACE2 gene polymorphism] affects the susceptibility to benazepril; [AGT gene polymorphism co-treated with AGTR1 gene polymorphism] affects the susceptibility to benazepril; [benazepril co-treated with Valsartan] results in decreased expression of AGT protein modified form; Valsartan inhibits the reaction [benazepril results in decreased expression of AGT protein] |
CTD |
PMID:10515446 PMID:11501062 PMID:11798627 PMID:12676074 PMID:17177138 PMID:17261659 PMID:18390891 PMID:19018797 PMID:20718632 PMID:20844835 PMID:21449848 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
decreases expression multiple interactions |
EXP ISO |
benazepril results in decreased expression of AGTR1A mRNA; benazepril results in decreased expression of AGTR1A protein [AGT gene polymorphism co-treated with AGTR1 gene polymorphism] affects the susceptibility to benazepril benazepril inhibits the reaction [Doxorubicin results in increased expression of AGTR1 protein] |
CTD |
PMID:9596920 PMID:15157388 PMID:21449848 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
decreases expression multiple interactions |
ISO |
benazepril results in decreased expression of AMBP protein benazepril promotes the reaction [Losartan results in decreased expression of AMBP protein]; Losartan promotes the reaction [benazepril results in decreased expression of AMBP protein] |
CTD |
PMID:16303729 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
Apob |
apolipoprotein B |
multiple interactions |
ISO |
[Valsartan co-treated with benazepril] results in decreased expression of APOB protein; fluvastatin promotes the reaction [[Valsartan co-treated with benazepril] results in decreased expression of APOB protein] |
CTD |
PMID:20671225 |
|
NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497
|
|
G |
Aqp1 |
aquaporin 1 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Glucose results in increased expression of AQP1 mRNA] |
CTD |
PMID:11510275 |
|
NCBI chr 4:84,482,512...84,494,690
Ensembl chr 4:84,482,512...84,494,690
|
|
G |
Aqp4 |
aquaporin 4 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Glucose results in increased expression of AQP4 mRNA] |
CTD |
PMID:11510275 |
|
NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
benazepril results in decreased expression of BAX protein |
CTD |
PMID:20026869 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression |
EXP |
benazepril results in increased expression of BCL2 protein |
CTD |
PMID:20026869 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases activity multiple interactions |
ISO EXP |
benazepril results in increased activity of BDKRB2 protein [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril |
CTD |
PMID:15339989 PMID:16982965 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Estrogens deficiency results in increased expression of CCL2 protein]; benazepril inhibits the reaction [Ethylene Glycol results in increased expression of CCL2 protein] |
CTD |
PMID:16284884 PMID:19553526 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Estrogens deficiency results in increased expression of CCL3 protein] |
CTD |
PMID:19553526 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Ethylene Glycol results in increased expression of CCL5 protein] |
CTD |
PMID:16284884 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression |
EXP |
benazepril results in decreased expression of CCN2 mRNA |
CTD |
PMID:17121042 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
benazepril results in increased expression of CD36 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression multiple interactions |
EXP |
benazepril results in decreased expression of COL4A1 mRNA benazepril inhibits the reaction [Streptozocin results in increased expression of COL4A1 mRNA] |
CTD |
PMID:11798618 PMID:16191423 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Estrogens deficiency results in increased expression of CXCL1 protein] |
CTD |
PMID:19553526 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
affects response to substance |
ISO |
CYP11B2 gene polymorphism affects the susceptibility to benazepril |
CTD |
PMID:16765146 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions increases activity |
EXP |
benazepril results in decreased expression of EDN1 mRNA; benazepril results in decreased expression of EDN1 protein [Valsartan co-treated with benazepril] results in decreased expression of EDN1 protein benazepril results in increased activity of EDN1 protein |
CTD |
PMID:7528292 PMID:11136700 PMID:16191423 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egln3 |
egl-9 family hypoxia-inducible factor 3 |
increases expression |
EXP |
benazepril results in increased expression of EGLN3 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 6:71,650,297...71,675,766
Ensembl chr 6:71,650,297...71,675,766
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
EXP |
benazepril inhibits the reaction [Doxorubicin results in increased expression of FAS protein]; benazepril promotes the reaction [Valsartan inhibits the reaction [Doxorubicin results in increased expression of FAS protein]]; Valsartan promotes the reaction [benazepril inhibits the reaction [Doxorubicin results in increased expression of FAS protein]] |
CTD |
PMID:15315341 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
EXP |
benazepril inhibits the reaction [Doxorubicin results in increased expression of FASLG protein]; benazepril promotes the reaction [Valsartan inhibits the reaction [Doxorubicin results in increased expression of FASLG protein]]; Valsartan promotes the reaction [benazepril inhibits the reaction [Doxorubicin results in increased expression of FASLG protein]] |
CTD |
PMID:15315341 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression multiple interactions |
EXP |
benazepril results in decreased expression of FN1 mRNA; benazepril results in decreased expression of FN1 protein benazepril inhibits the reaction [Doxorubicin results in increased expression of FN1 protein]; benazepril inhibits the reaction [Streptozocin results in increased expression of FN1 mRNA] |
CTD |
PMID:10515446 PMID:11798618 PMID:16191423 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
EXP |
benazepril results in increased expression of FOS mRNA |
CTD |
PMID:8539265 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Got2 |
glutamic-oxaloacetic transaminase 2 |
increases expression |
EXP |
benazepril results in increased expression of GOT2 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr19:9,174,304...9,199,995
Ensembl chr19:9,174,311...9,199,994
|
|
G |
Hgf |
hepatocyte growth factor |
increases expression |
EXP |
benazepril results in increased expression of HGF mRNA |
CTD |
PMID:16696918 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Hspe1 |
heat shock protein family E (Hsp10) member 1 |
increases expression |
EXP |
benazepril results in increased expression of HSPE1 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Ethylene Glycol results in increased expression of IL6 protein] |
CTD |
PMID:16284884 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions increases expression |
EXP |
benazepril promotes the reaction [Valsartan results in increased expression of KNG1 protein modified form]; PD 123319 inhibits the reaction [benazepril promotes the reaction [Valsartan results in increased expression of KNG1 protein modified form]]; PD 123319 inhibits the reaction [Valsartan promotes the reaction [benazepril results in increased expression of KNG1 protein modified form]]; Valsartan promotes the reaction [benazepril results in increased expression of KNG1 protein modified form] |
CTD |
PMID:11509473 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases expression |
EXP |
benazepril results in increased expression of MAPK1 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Me1 |
malic enzyme 1 |
increases expression |
EXP |
benazepril results in increased expression of ME1 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Doxorubicin results in decreased expression of MMP2 mRNA]; benazepril inhibits the reaction [Doxorubicin results in decreased expression of MMP2 protein]; benazepril inhibits the reaction [Streptozocin results in decreased expression of MMP2 mRNA]; benazepril inhibits the reaction [Streptozocin results in decreased expression of MMP2 protein] |
CTD |
PMID:16732983 PMID:19357873 PMID:20821936 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases activity decreases expression multiple interactions |
ISO EXP |
benazepril results in increased activity of MMP9 protein benazepril results in decreased expression of MMP9 protein benazepril inhibits the reaction [Doxorubicin results in decreased expression of MMP9 mRNA]; benazepril inhibits the reaction [Doxorubicin results in decreased expression of MMP9 protein] |
CTD |
PMID:15339989 PMID:19357873 PMID:20981132 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
affects response to substance |
ISO |
MTHFR gene polymorphism affects the susceptibility to benazepril; MTHFR gene SNP affects the susceptibility to benazepril |
CTD |
PMID:16081343 PMID:20445573 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Mtr |
5-methyltetrahydrofolate-homocysteine methyltransferase |
affects response to substance |
ISO |
MTR gene SNP affects the susceptibility to benazepril; MTR protein polymorphism affects the susceptibility to benazepril |
CTD |
PMID:15148588 PMID:20445573 |
|
NCBI chr17:58,219,998...58,308,560
Ensembl chr17:58,220,071...58,304,822
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
increases expression |
EXP |
benazepril results in increased expression of MYC mRNA |
CTD |
PMID:8539265 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions |
EXP |
[Valsartan co-treated with benazepril] results in increased expression of MYH6 mRNA |
CTD |
PMID:11136700 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
decreases expression |
EXP |
benazepril results in decreased expression of NCF1 mRNA |
CTD |
PMID:19018797 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Ethylene Glycol results in increased expression of NFKB1 protein] |
CTD |
PMID:16284884 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
EXP |
benazepril inhibits the reaction [Streptozocin results in decreased expression of NFKBIA mRNA] |
CTD |
PMID:17900838 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression |
EXP |
benazepril results in decreased expression of NOS2 mRNA; benazepril results in decreased expression of NOS2 protein |
CTD |
PMID:16191423 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions decreases expression |
EXP |
[Valsartan co-treated with benazepril] results in decreased expression of NPPA mRNA benazepril results in decreased expression of NPPA mRNA |
CTD |
PMID:8763405 PMID:11136700 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions decreases expression |
EXP |
[Valsartan co-treated with benazepril] results in decreased expression of NPPB mRNA benazepril results in decreased expression of NPPB mRNA |
CTD |
PMID:11136700 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
benazepril inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pcna |
proliferating cell nuclear antigen |
decreases expression |
EXP |
benazepril results in decreased expression of PCNA protein |
CTD |
PMID:17121042 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pdk4 |
pyruvate dehydrogenase kinase 4 |
increases expression |
EXP |
benazepril results in increased expression of PDK4 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850
|
|
G |
Pla2g5 |
phospholipase A2, group V |
decreases expression |
EXP |
benazepril results in decreased expression of PLA2G5 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Plau |
plasminogen activator, urokinase |
multiple interactions |
EXP |
benazepril inhibits the reaction [Streptozocin results in increased expression of PLAU mRNA] |
CTD |
PMID:15322501 |
|
NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775
|
|
G |
Plaur |
plasminogen activator, urokinase receptor |
multiple interactions |
EXP |
benazepril inhibits the reaction [Streptozocin results in increased expression of PLAUR mRNA] |
CTD |
PMID:15322501 |
|
NCBI chr 1:80,053,441...80,068,384
Ensembl chr 1:80,050,324...80,068,595
|
|
G |
Plg |
plasminogen |
increases activity multiple interactions |
ISO |
benazepril results in increased activity of PLG protein FR 173657 inhibits the reaction [benazepril results in increased activity of PLG protein] |
CTD |
PMID:15339989 |
|
NCBI chr 1:48,325,186...48,367,643
Ensembl chr 1:48,325,185...48,367,786
|
|
G |
Prcp |
prolylcarboxypeptidase |
affects response to substance |
ISO |
PRCP gene SNP affects the susceptibility to benazepril |
CTD |
PMID:20079160 |
|
NCBI chr 1:146,931,487...146,983,891
Ensembl chr 1:146,930,561...146,984,530
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions decreases expression decreases phosphorylation |
EXP |
benazepril inhibits the reaction [Doxorubicin results in increased expression of RELA mRNA]; benazepril inhibits the reaction [Streptozocin results in increased expression of RELA mRNA] benazepril results in decreased expression of RELA mRNA; benazepril results in decreased expression of RELA protein benazepril results in decreased phosphorylation of RELA protein |
CTD |
PMID:15157388 PMID:17900838 PMID:19018797 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
increases expression increases activity multiple interactions |
ISO EXP |
benazepril results in increased expression of REN protein benazepril results in increased activity of REN protein [benazepril co-treated with Valsartan] results in increased activity of REN protein |
CTD |
PMID:1316404 PMID:10836730 PMID:11501062 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
decreases expression |
EXP |
benazepril results in decreased expression of RSAD2 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699
|
|
G |
Serpine1 |
serpin family E member 1 |
decreases expression multiple interactions |
ISO EXP |
benazepril results in decreased expression of SERPINE1 mRNA; benazepril results in decreased expression of SERPINE1 protein FR 173657 inhibits the reaction [benazepril results in decreased expression of SERPINE1 mRNA] benazepril inhibits the reaction [Streptozocin results in increased expression of SERPINE1 mRNA] |
CTD |
PMID:15322501 PMID:15339989 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Serpinh1 |
serpin family H member 1 |
increases expression |
EXP |
benazepril results in increased expression of SERPINH1 mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions |
ISO |
benazepril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
multiple interactions |
ISO EXP |
benazepril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
|
|
G |
Smad2 |
SMAD family member 2 |
affects expression multiple interactions |
EXP |
benazepril affects the expression of SMAD2 mRNA; benazepril affects the expression of SMAD2 protein [benazepril co-treated with irbesartan] affects the expression of SMAD2 mRNA; [benazepril co-treated with irbesartan] affects the expression of SMAD2 protein |
CTD |
PMID:16635409 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad3 |
SMAD family member 3 |
affects expression multiple interactions |
EXP |
benazepril affects the expression of SMAD3 mRNA; benazepril affects the expression of SMAD3 protein [benazepril co-treated with candesartan] results in decreased expression of SMAD3 protein; [benazepril co-treated with irbesartan] affects the expression of SMAD3 mRNA; [benazepril co-treated with irbesartan] affects the expression of SMAD3 protein |
CTD |
PMID:16635409 PMID:19487956 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Snrpn |
small nuclear ribonucleoprotein polypeptide N |
decreases expression |
EXP |
benazepril results in decreased expression of SNRPN mRNA |
CTD |
PMID:14871019 |
|
NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
[benazepril co-treated with Valsartan] results in increased expression of SOD1 protein |
CTD |
PMID:20445533 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
decreases expression |
EXP |
benazepril results in decreased expression of SPP1 mRNA |
CTD |
PMID:11867951 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
affects expression decreases expression multiple interactions |
EXP ISO |
benazepril affects the expression of TGFB1 mRNA benazepril results in decreased expression of TGFB1 mRNA; benazepril results in decreased expression of TGFB1 protein [benazepril co-treated with Valsartan] results in decreased expression of TGFB1 protein [benazepril co-treated with candesartan] results in decreased expression of TGFB1 protein; [benazepril co-treated with Irbesartan] affects the expression of TGFB1 mRNA; benazepril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 mRNA]; benazepril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; benazepril inhibits the reaction [Streptozocin results in increased expression of TGFB1 mRNA]; benazepril inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] |
CTD |
PMID:10515446 PMID:11798627 PMID:11867951 PMID:16191423 PMID:16409969 PMID:16523407 PMID:16635409 PMID:17177138 PMID:18390891 PMID:19018797 PMID:19487956 PMID:20493835 PMID:20844835 More...
|
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Streptozocin results in increased expression of TGFBR1 mRNA]; benazepril inhibits the reaction [Streptozocin results in increased expression of TGFBR1 protein] |
CTD |
PMID:11798618 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression multiple interactions |
EXP |
benazepril results in decreased expression of TIMP1 mRNA; benazepril results in decreased expression of TIMP1 protein benazepril inhibits the reaction [Doxorubicin results in increased expression of TIMP1 mRNA]; benazepril inhibits the reaction [Doxorubicin results in increased expression of TIMP1 protein] |
CTD |
PMID:11867951 PMID:18471418 PMID:19357873 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
EXP |
benazepril inhibits the reaction [Streptozocin results in increased expression of TIMP2 mRNA]; benazepril inhibits the reaction [Streptozocin results in increased expression of TIMP2 protein] |
CTD |
PMID:16732983 PMID:20821936 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tlr4 |
toll-like receptor 4 |
decreases expression |
ISO |
benazepril results in decreased expression of TLR4 protein |
CTD |
PMID:20981132 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
benazepril results in decreased expression of TNF protein [benazepril co-treated with Amlodipine] results in decreased expression of TNF protein |
CTD |
PMID:16775501 PMID:20981132 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
decreases expression |
EXP |
benazepril results in decreased expression of VCAM1 mRNA; benazepril results in decreased expression of VCAM1 protein |
CTD |
PMID:19018797 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
benazepril inhibits the reaction [Streptozocin results in increased expression of VEGFA protein] |
CTD |
PMID:20844835 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases ubiquitination |
ISO |
bixin results in decreased ubiquitination of NFE2L2 protein |
CTD |
PMID:30698894 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
|
G |
Ace |
angiotensin I converting enzyme |
affects response to substance |
ISO |
ACE gene polymorphism affects the susceptibility to Cilazapril |
CTD |
PMID:15498266 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
Cilazapril results in increased expression of ADIPOQ protein |
CTD |
PMID:19789415 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions |
EXP |
[Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Cilazapril promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA] |
CTD |
PMID:15331931 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions |
EXP |
[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Cilazapril inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA] |
CTD |
PMID:15331931 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
decreases expression |
EXP |
Cilazapril results in decreased expression of FGF2 mRNA; Cilazapril results in decreased expression of FGF2 protein |
CTD |
PMID:9640960 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions affects secretion |
ISO |
[Cilazapril co-treated with Verapamil] affects the secretion of NPPA protein Cilazapril affects the secretion of NPPA protein |
CTD |
PMID:1457087 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Ren |
renin |
increases activity |
EXP |
Cilazapril results in increased activity of REN protein |
CTD |
PMID:2425185 |
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Slc15a1 |
solute carrier family 15 member 1 |
multiple interactions |
ISO |
Cilazapril inhibits the reaction [SLC15A1 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr15:98,537,641...98,582,544
Ensembl chr15:98,537,641...98,582,545
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
multiple interactions |
EXP |
Cilazapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Cilazapril inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein] |
CTD |
PMID:15331931 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
multiple interactions |
ISO |
crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] |
CTD |
PMID:30580027 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in decreased expression of BAMBI mRNA] |
CTD |
PMID:32259551 |
|
NCBI chr17:54,121,251...54,125,816
Ensembl chr17:54,121,255...54,126,060
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of BAX protein]; crocin inhibits the reaction [Diazinon results in increased expression of BAX mRNA]; crocin inhibits the reaction [Diazinon results in increased expression of BAX protein] crocin results in increased expression of BAX mRNA |
CTD |
PMID:23523949 PMID:27353299 PMID:32886819 PMID:32920515 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions decreases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2 protein] crocin results in decreased expression of BCL2 mRNA [crocin co-treated with Paraquat] results in decreased expression of BCL2 mRNA |
CTD |
PMID:31911963 PMID:32886819 PMID:32920515 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
increases expression |
EXP |
crocin results in increased expression of BDNF mRNA; crocin results in increased expression of BDNF protein |
CTD |
PMID:24401376 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
decreases expression |
ISO |
crocin results in decreased expression of BIRC5 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression increases activity increases cleavage |
EXP ISO |
crocin affects the reaction [Ethanol results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of CASP3 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased activity of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased cleavage of CASP3 protein]; crocin inhibits the reaction [Diazinon results in increased expression of CASP3 protein modified form]; crocin inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; crocin inhibits the reaction [Ethanol results in increased activity of CASP3 protein] crocin results in increased expression of CASP3 mRNA crocin results in increased activity of CASP3 protein crocin inhibits the reaction [Paraquat results in increased expression of CASP3 mRNA] Acetylcysteine inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein] |
CTD |
PMID:23523949 PMID:25637687 PMID:25899501 PMID:26807765 PMID:27353299 PMID:30672053 PMID:31911963 PMID:32886819 PMID:32920515 PMID:35085590 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
crocin results in increased activity of CASP8 protein |
CTD |
PMID:32886819 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
EXP ISO |
crocin inhibits the reaction [Diazinon results in increased cleavage of CASP9 protein] crocin results in increased activity of CASP9 protein |
CTD |
PMID:27353299 PMID:32886819 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases activity increases activity |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in decreased activity of CAT protein]; crocin inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]; crocin inhibits the reaction [Streptozocin results in decreased activity of CAT protein] crocin results in decreased activity of CAT protein crocin inhibits the reaction [Patulin results in increased activity of CAT protein] crocin results in increased activity of CAT protein |
CTD |
PMID:25899501 PMID:26584762 PMID:29409856 PMID:32886819 PMID:32920515 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
crocin results in decreased expression of CCND1 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
crocin inhibits the reaction [Diazinon results in increased activity of CKM protein] |
CTD |
PMID:23523949 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of Pantothenic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in decreased abundance of phenylpyruvic acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Allantoin]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Amino Acids]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Carnitine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Citric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Creatinine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of phenylacetylglycine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Succinic Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uric Acid]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased abundance of Uridine]; [geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein] |
CTD |
PMID:24709313 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
crocin results in increased expression of and results in increased phosphorylation of CREB1 protein |
CTD |
PMID:24401376 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
EXP |
crocin inhibits the reaction [Diazinon affects the localization of CYCS protein] |
CTD |
PMID:23523949 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity multiple interactions |
EXP |
crocin results in decreased activity of CYP2E1 protein crocin inhibits the reaction [Carbon Tetrachloride results in increased activity of CYP2E1 protein] |
CTD |
PMID:25899501 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Glo1 |
glyoxalase 1 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein] |
CTD |
PMID:30580027 |
|
NCBI chr20:8,663,617...8,681,661
Ensembl chr20:8,662,801...8,681,649
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased activity of GPT protein] |
CTD |
PMID:32259551 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of HMOX1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa1l |
heat shock protein family A (Hsp70) member 1 like |
multiple interactions |
EXP |
crocin inhibits the reaction [Ethanol results in increased expression of HSPA1L mRNA] |
CTD |
PMID:25637687 |
|
NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
EXP |
crocin inhibits the reaction [Doxorubicin results in decreased expression of IL10 protein] |
CTD |
PMID:26807765 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
[geniposide co-treated with phellodendrine co-treated with magnoflorine co-treated with Chlorogenic Acid co-treated with crocin co-treated with Flavonoids co-treated with Berberine Alkaloids] inhibits the reaction [[COL2A1 protein co-treated with Freund's Adjuvant] results in increased secretion of IL1B protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of IL1B protein] |
CTD |
PMID:24709313 PMID:26807765 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions decreases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of IL6 protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; crocin inhibits the reaction [Ethanol results in decreased expression of IL6 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of IL6 protein] crocin results in decreased expression of IL6 mRNA |
CTD |
PMID:25637687 PMID:25899501 PMID:29409856 PMID:32886819 PMID:32920515 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
crocin affects the expression of and affects the phosphorylation of JAK2 protein |
CTD |
PMID:32886819 |
|
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of KEAP1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
EXP |
crocin inhibits the reaction [Diazinon results in decreased expression of LDLR mRNA] |
CTD |
PMID:24132704 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
EXP ISO |
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK1 protein] crocin results in decreased phosphorylation of MAPK1 protein |
CTD |
PMID:24132704 PMID:28689058 PMID:32886819 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
EXP ISO |
crocin inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; crocin inhibits the reaction [Diazinon results in decreased phosphorylation of MAPK3 protein] crocin results in decreased phosphorylation of MAPK3 protein crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA] |
CTD |
PMID:24132704 PMID:28689058 PMID:30580027 PMID:32886819 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mir122 |
microRNA 122 |
multiple interactions |
EXP |
crocin inhibits the reaction [bisphenol A results in increased expression of MIR122 mRNA] |
CTD |
PMID:28689058 |
|
NCBI chr18:58,758,703...58,758,787
|
|
G |
Mir29b1 |
microRNA 29b-1 |
increases expression multiple interactions |
EXP |
crocin results in increased expression of MIR29B1 mRNA Cisplatin inhibits the reaction [crocin results in increased expression of MIR29B1 mRNA]; crocin inhibits the reaction [Cisplatin results in decreased expression of MIR29B1 mRNA] |
CTD |
PMID:32259551 |
|
NCBI chr 4:59,650,987...59,651,067
Ensembl chr 4:59,650,986...59,651,067
|
|
G |
Mir34a |
microRNA 34a |
multiple interactions |
ISO |
MIR34A mRNA inhibits the reaction [crocin results in increased activity of CASP3 protein]; MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein] |
CTD |
PMID:35085590 |
|
NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
crocin inhibits the reaction [Ethanol results in increased activity of MPO protein] |
CTD |
PMID:25637687 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
decreases expression |
ISO |
crocin results in decreased expression of MYC mRNA |
CTD |
PMID:32886819 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Mycn |
MYCN proto-oncogene, bHLH transcription factor |
decreases response to substance decreases expression multiple interactions |
ISO |
MYCN results in decreased susceptibility to crocin crocin results in decreased expression of MYCN protein crocin results in decreased expression of and results in decreased stability of MYCN mRNA; MYCN protein inhibits the reaction [crocin results in increased cleavage of CASP3 protein]; MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] |
CTD |
PMID:30672053 |
|
NCBI chr 6:35,717,764...35,723,590
Ensembl chr 6:35,717,764...35,723,590
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of MYD88 protein] |
CTD |
PMID:32259551 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NFE2L2 protein]; crocin inhibits the reaction [Cisplatin results in decreased expression of NFE2L2 protein] |
CTD |
PMID:32259551 PMID:32920515 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in decreased expression of NQO1 protein] |
CTD |
PMID:32920515 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Ostm1 |
osteoclastogenesis associated transmembrane protein 1 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr20:46,071,657...46,187,049
Ensembl chr20:46,153,075...46,187,023
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
crocin results in increased cleavage of PARP1 protein MYCN protein inhibits the reaction [crocin results in increased cleavage of PARP1 protein] |
CTD |
PMID:30672053 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression |
ISO |
crocin results in decreased expression of PTGS2 mRNA |
CTD |
PMID:32886819 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptpn4 |
protein tyrosine phosphatase, non-receptor type 4 |
multiple interactions increases expression |
ISO |
MIR34A mRNA inhibits the reaction [crocin results in increased expression of PTPN4 protein]; PTPN4 protein affects the reaction [crocin results in increased activity of CASP3 protein] |
CTD |
PMID:35085590 |
|
NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of RELA protein]; crocin inhibits the reaction [Streptozocin results in increased expression of RELA protein] |
CTD |
PMID:29409856 PMID:32920515 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Smad2 |
SMAD family member 2 |
decreases expression multiple interactions |
EXP |
crocin results in decreased expression of SMAD2 protein Cisplatin inhibits the reaction [crocin results in decreased expression of SMAD2 protein]; crocin inhibits the reaction [Cisplatin results in increased expression of SMAD2 protein] |
CTD |
PMID:32259551 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
crocin affects the expression of and affects the phosphorylation of STAT3 protein |
CTD |
PMID:32886819 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of TGFB1 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein] |
CTD |
PMID:29409856 PMID:32259551 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of TGFBR1 protein] |
CTD |
PMID:32259551 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 mRNA]; crocin inhibits the reaction [Cisplatin results in increased expression of TLR4 protein]; crocin inhibits the reaction [Streptozocin results in increased expression of TLR4 protein] |
CTD |
PMID:29409856 PMID:32259551 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
EXP ISO |
crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF mRNA]; crocin inhibits the reaction [Arsenic Trioxide results in increased expression of TNF protein]; crocin inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; crocin inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; crocin inhibits the reaction [Ethanol results in decreased expression of TNF protein] crocin results in decreased expression of TNF mRNA |
CTD |
PMID:25637687 PMID:25899501 PMID:26807765 PMID:32886819 PMID:32920515 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
multiple interactions |
ISO |
[crocin co-treated with pyrazolanthrone co-treated with TNFSF11 protein] results in decreased expression of OSTM1 mRNA; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of AKT2 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of MAPK3 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of OSTM1 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA]; crocin inhibits the reaction [[TNFSF11 protein co-treated with Pyruvaldehyde] results in decreased activity of GLO1 protein]; crocin promotes the reaction [pyrazolanthrone inhibits the reaction [TNFSF11 protein results in increased activity of ACP5 protein]] |
CTD |
PMID:30580027 |
|
NCBI chr15:53,674,990...53,705,171
Ensembl chr15:53,673,877...53,705,445
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
crocin inhibits the reaction [Doxorubicin results in increased expression of TNNT2 protein] |
CTD |
PMID:26807765 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
crocin inhibits the reaction [Paraquat results in increased expression of TRP53 mRNA] |
CTD |
PMID:31911963 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
crocin inhibits the reaction [[TNFSF11 protein co-treated with pyrazolanthrone] results in increased expression of TRAF6 mRNA] |
CTD |
PMID:30580027 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vgf |
VGF nerve growth factor inducible |
increases expression |
EXP |
crocin results in increased expression of VGF protein |
CTD |
PMID:24401376 |
|
NCBI chr12:19,637,313...19,645,123
Ensembl chr12:19,637,320...19,640,341
|
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases transport |
ISO |
ABCC4 protein results in increased transport of Enalapril |
CTD |
PMID:17939016 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity multiple interactions increases expression |
ISO EXP |
Enalapril results in decreased activity of ACE protein Enalapril inhibits the reaction [Dexamethasone results in increased expression of ACE protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of ACE protein]] ACE gene polymorphism affects the susceptibility to [Enalapril co-treated with Sodium Chloride]; ACE gene polymorphism inhibits the reaction [[Enalapril co-treated with Sodium Chloride] results in increased susceptibility to AGT protein modified form] Enalapril results in increased expression of ACE mRNA Enalapril inhibits the reaction [Streptozocin results in increased expression of ACE mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of ACE protein]; Enalapril promotes the reaction [Folic Acid results in increased expression of ACE mRNA] |
CTD |
PMID:15728788 PMID:15816410 PMID:20679179 PMID:20829712 PMID:23733546 PMID:28973481 PMID:30940551 More...
|
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression |
EXP |
Enalapril results in decreased expression of ACTA2 protein |
CTD |
PMID:19349682 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
decreases expression |
EXP |
Enalapril results in decreased expression of ACVRL1 protein |
CTD |
PMID:12883979 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
Enalapril results in increased expression of ADIPOQ protein |
CTD |
PMID:25037058 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
increases expression |
EXP |
Enalapril results in increased expression of ADRB1 protein |
CTD |
PMID:7586371 |
|
NCBI chr 1:255,772,217...255,773,617
Ensembl chr 1:255,771,597...255,807,259
|
|
G |
Agt |
angiotensinogen |
decreases activity affects response to substance increases expression decreases response to substance multiple interactions decreases expression |
EXP ISO |
Enalapril results in decreased activity of AGT protein modified form AGT gene alternative form affects the susceptibility to Enalapril; AGT protein polymorphism affects the susceptibility to Enalapril Enalapril results in increased expression of AGT mRNA Enalapril results in decreased susceptibility to AGT protein modified form Enalapril affects the reaction [chymostatin results in decreased susceptibility to AGT protein modified form]; Enalapril inhibits the reaction [Cyclosporine results in increased expression of AGT protein]; Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of AGT protein] Enalapril results in decreased expression of AGT protein modified form [Enalapril co-treated with Sodium Chloride] results in increased susceptibility to AGT protein modified form; ACE gene polymorphism inhibits the reaction [[Enalapril co-treated with Sodium Chloride] results in increased susceptibility to AGT protein modified form]; Enalapril inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone] Enalapril results in decreased expression of AGT mRNA |
CTD |
PMID:1330361 PMID:2474097 PMID:6319675 PMID:12003776 PMID:12911327 PMID:14659064 PMID:16685205 PMID:18300870 PMID:18679781 PMID:18796534 PMID:19114890 PMID:20829712 PMID:21602471 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
affects expression multiple interactions decreases expression increases expression |
EXP ISO |
Enalapril affects the expression of AGTR1A mRNA Enalapril inhibits the reaction [Dexamethasone results in increased expression of AGTR1 protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in increased expression of AGTR1 protein]] Enalapril results in decreased expression of AGTR1A mRNA Enalapril inhibits the reaction [Cyclosporine results in decreased expression of AGTR1A mRNA] Enalapril results in increased expression of AGTR1A mRNA |
CTD |
PMID:14659064 PMID:18403896 PMID:18765277 PMID:18796534 PMID:30940551 |
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
increases expression decreases expression |
EXP |
Enalapril results in increased expression of AGTR2 mRNA Enalapril results in decreased expression of AGTR2 mRNA |
CTD |
PMID:9740612 PMID:18403896 PMID:18765277 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
EXP |
Enalapril promotes the reaction [Isoproterenol results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:18806606 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Corticosterone results in decreased expression of ALPL mRNA]; Enalapril inhibits the reaction [Ethanol results in decreased expression of ALPL mRNA] |
CTD |
PMID:30423288 PMID:31887396 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Ang |
angiogenin |
decreases expression |
ISO |
Enalapril results in decreased expression of ANG protein |
CTD |
PMID:3038326 |
|
NCBI chr15:24,317,733...24,323,361
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Streptozocin results in increased expression of ANGPT2 mRNA] |
CTD |
PMID:19958114 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[Bezafibrate co-treated with Enalapril co-treated with Dipyridamole co-treated with Atorvastatin co-treated with Valsartan] results in decreased expression of APOE protein Enalapril inhibits the reaction [APOE gene mutant form results in decreased abundance of Antioxidants]; Enalapril inhibits the reaction [APOE gene mutant form results in increased abundance of Cholesterol] |
CTD |
PMID:19603250 PMID:25037058 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Atf2 |
activating transcription factor 2 |
increases expression |
EXP |
Enalapril results in increased expression of ATF2 protein |
CTD |
PMID:15531746 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
increases expression |
EXP |
Enalapril results in increased expression of ATP1A2 mRNA; Enalapril results in increased expression of ATP1A2 protein |
CTD |
PMID:18418421 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Enalapril results in decreased expression of ATP1A3 mRNA; Enalapril results in decreased expression of ATP1A3 protein |
CTD |
PMID:18418421 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
Enalapril promotes the reaction [Dexamethasone results in increased activity of AVP protein] |
CTD |
PMID:3346065 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression |
EXP |
Enalapril results in decreased expression of BAX protein |
CTD |
PMID:21153712 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
increases expression multiple interactions |
EXP |
Enalapril results in increased expression of BCL2 protein Enalapril inhibits the reaction [Isoproterenol results in decreased expression of BCL2 protein] |
CTD |
PMID:21153712 PMID:30623541 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
increases expression multiple interactions |
EXP |
Enalapril results in increased expression of BDKRB1 mRNA [kallidin, des-Arg(10)- results in decreased activity of BDKRB1 protein] which results in decreased susceptibility to Enalapril |
CTD |
PMID:18796534 PMID:21430409 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases expression |
EXP |
Enalapril results in increased expression of BDKRB2 mRNA; Enalapril results in increased expression of BDKRB2 protein |
CTD |
PMID:18190998 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Corticosterone results in decreased expression of BGLAP mRNA]; Enalapril inhibits the reaction [Ethanol results in decreased expression of BGLAP mRNA] |
CTD |
PMID:30423288 PMID:31887396 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Car2 |
carbonic anhydrase 2 |
decreases activity |
ISO |
Enalapril results in decreased activity of CA2 protein |
CTD |
PMID:28126276 |
|
NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818
|
|
G |
Casp3 |
caspase 3 |
decreases activity multiple interactions |
EXP |
Enalapril results in decreased activity of CASP3 protein Enalapril inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein] |
CTD |
PMID:21153712 PMID:30623541 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
decreases activity |
EXP |
Enalapril results in decreased activity of CASP9 protein |
CTD |
PMID:21153712 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity multiple interactions |
EXP |
Enalapril results in increased activity of CAT protein Enalapril inhibits the reaction [Isoproterenol results in decreased expression of CAT protein] |
CTD |
PMID:12124199 PMID:30623541 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression multiple interactions |
ISO EXP |
Enalapril results in decreased expression of CCL2 protein [paricalcitol co-treated with Enalapril] results in decreased expression of CCL2 protein Enalapril inhibits the reaction [sodium arsenite results in increased secretion of CCL2 protein] Enalapril results in decreased expression of CCL2 mRNA |
CTD |
PMID:10925121 PMID:17513326 PMID:19627010 PMID:20720404 PMID:25037058 PMID:28973481 More...
|
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases expression multiple interactions |
EXP ISO |
Enalapril results in decreased expression of CCN2 mRNA; Enalapril results in decreased expression of CCN2 protein Enalapril inhibits the reaction [Streptozocin results in increased expression of CCN2 protein] |
CTD |
PMID:18812665 PMID:19349682 PMID:21416479 PMID:25037058 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Cela2a |
chymotrypsin like elastase 2A |
decreases expression |
EXP |
Enalapril results in decreased expression of CELA2A mRNA |
CTD |
PMID:21602471 |
|
NCBI chr 5:154,126,879...154,136,630
Ensembl chr 5:154,126,878...154,136,632
|
|
G |
Cltrn |
collectrin, amino acid transport regulator |
decreases expression |
EXP |
Enalapril results in decreased expression of CLTRN mRNA; Enalapril results in decreased expression of CLTRN protein |
CTD |
PMID:12887829 |
|
NCBI chr X:30,361,967...30,395,264
Ensembl chr X:30,361,967...30,395,349
|
|
G |
Clu |
clusterin |
decreases expression |
EXP |
Enalapril results in decreased expression of CLU protein |
CTD |
PMID:12193663 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cma1 |
chymase 1 |
decreases expression |
EXP |
Enalapril results in decreased expression of CMA1 mRNA |
CTD |
PMID:18796534 |
|
NCBI chr15:29,417,451...29,420,233
Ensembl chr15:29,417,451...29,420,233
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
Enalapril inhibits the reaction [Bleomycin results in increased expression of COL1A1 mRNA] |
CTD |
PMID:12003776 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
increases expression decreases expression |
ISO EXP |
Enalapril results in increased expression of COL3A1 mRNA Enalapril results in decreased expression of COL3A1 mRNA |
CTD |
PMID:17164399 PMID:25037058 |
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
multiple interactions decreases expression |
EXP |
[eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; [eplerenone co-treated with Enalapril] results in decreased expression of COL4A1 mRNA; [eplerenone co-treated with Enalapril] results in decreased expression of COL4A1 protein; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of COL4A1 mRNA]]; Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of COL4A1 mRNA] Enalapril results in decreased expression of COL4A1 mRNA; Enalapril results in decreased expression of COL4A1 protein |
CTD |
PMID:9175058 PMID:18682491 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Cyba |
cytochrome b-245 alpha chain |
decreases expression multiple interactions |
ISO |
Enalapril results in decreased expression of CYBA protein [paricalcitol co-treated with Enalapril] results in decreased expression of CYBA protein |
CTD |
PMID:20720404 PMID:25037058 |
|
NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
EXP |
Enalapril affects the localization of CYCS protein |
CTD |
PMID:21153712 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Enalapril inhibits the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin] |
CTD |
PMID:19299527 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of EDN1 mRNA] |
CTD |
PMID:9175058 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Eng |
endoglin |
multiple interactions |
ISO |
[Enalapril co-treated with paricalcitol] results in decreased expression of ENG mRNA |
CTD |
PMID:25037058 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
Epo |
erythropoietin |
decreases expression multiple interactions |
ISO EXP |
Enalapril results in decreased expression of EPO protein Enalapril inhibits the reaction [Streptozocin results in increased expression of EPO mRNA] |
CTD |
PMID:2474097 PMID:9434678 PMID:19958114 |
|
NCBI chr12:19,204,258...19,207,948
Ensembl chr12:19,204,508...19,207,946
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Streptozocin results in increased expression of EPOR mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of EPOR protein] |
CTD |
PMID:19958114 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression multiple interactions |
ISO |
Enalapril results in decreased expression of F3 protein Enalapril inhibits the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein] |
CTD |
PMID:18060435 PMID:22188725 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faslg |
Fas ligand |
decreases expression |
EXP |
Enalapril results in decreased expression of FASLG mRNA |
CTD |
PMID:10925121 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Gh1 |
growth hormone 1 |
increases response to substance |
ISO |
GH1 protein results in increased susceptibility to Enalapril |
CTD |
PMID:12883983 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gja5 |
gap junction protein, alpha 5 |
multiple interactions |
ISO |
GJA5 affects the reaction [Enalapril results in increased secretion of REN protein] |
CTD |
PMID:19109587 |
|
NCBI chr 2:184,602,407...184,621,952
Ensembl chr 2:184,564,475...184,621,952
|
|
G |
Gjc1 |
gap junction protein, gamma 1 |
multiple interactions |
ISO |
GJC1 affects the reaction [Enalapril results in increased secretion of REN protein] |
CTD |
PMID:19109587 |
|
NCBI chr10:87,758,192...87,785,443
Ensembl chr10:87,760,528...87,785,867
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Isoproterenol results in decreased phosphorylation of GSK3B protein] |
CTD |
PMID:18806606 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Has2 |
hyaluronan synthase 2 |
increases expression |
EXP |
Enalapril results in increased expression of HAS2 mRNA |
CTD |
PMID:20933085 |
|
NCBI chr 7:88,113,326...88,139,337
Ensembl chr 7:88,113,326...88,128,933
|
|
G |
Hmgb1 |
high mobility group box 1 |
multiple interactions |
EXP ISO |
Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of HMGB1 protein] Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased secretion of HMGB1 protein] |
CTD |
PMID:19114890 |
|
NCBI chr12:5,973,062...5,978,565
Ensembl chr12:5,901,586...5,978,565
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
EXP |
Enalapril results in increased expression of HMOX1 protein |
CTD |
PMID:21263376 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hyal1 |
hyaluronidase 1 |
decreases expression |
EXP |
Enalapril results in decreased expression of HYAL1 mRNA; Enalapril results in decreased expression of HYAL1 protein |
CTD |
PMID:20933085 |
|
NCBI chr 8:108,250,654...108,254,526
Ensembl chr 8:108,250,667...108,260,210
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression multiple interactions |
EXP ISO |
Enalapril results in decreased expression of ICAM1 protein [Enalapril co-treated with paricalcitol] results in decreased expression of ICAM1 mRNA Enalapril results in decreased expression of ICAM1 protein modified form Enalapril inhibits the reaction [sodium arsenite results in increased secretion of ICAM1 protein modified form] |
CTD |
PMID:14716214 PMID:17347482 PMID:25037058 PMID:28973481 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression decreases expression |
EXP |
Enalapril affects the expression of IGF1 protein Enalapril results in decreased expression of IGF1 mRNA |
CTD |
PMID:12883983 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Igfbp1 |
insulin-like growth factor binding protein 1 |
increases expression |
EXP |
Enalapril results in increased expression of IGFBP1 mRNA |
CTD |
PMID:12883983 |
|
NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
Enalapril inhibits the reaction [IL1A protein results in increased expression of VEGFA mRNA]; Enalapril inhibits the reaction [IL1A protein results in increased expression of VEGFA protein] |
CTD |
PMID:17299153 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions decreases expression |
EXP ISO |
Enalapril inhibits the reaction [Acrolein results in increased expression of IL1B mRNA]; Enalapril inhibits the reaction [Acrolein results in increased expression of IL1B protein]; Enalapril inhibits the reaction [Streptozocin results in increased expression of IL1B mRNA] Enalapril results in decreased expression of IL1B mRNA |
CTD |
PMID:17167242 PMID:21265103 PMID:25037058 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions affects response to substance |
EXP ISO |
Enalapril inhibits the reaction [Acrolein results in increased expression of IL6 mRNA]; Enalapril inhibits the reaction [Acrolein results in increased expression of IL6 protein]; Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of IL6 protein]; Enalapril inhibits the reaction [Isoproterenol results in increased expression of IL6 protein]; Enalapril inhibits the reaction [Streptozocin results in increased expression of IL6 mRNA] Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased secretion of IL6 protein] IL6 gene polymorphism affects the susceptibility to Enalapril |
CTD |
PMID:15342284 PMID:17167242 PMID:19114890 PMID:21265103 PMID:30623541 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irak1 |
interleukin-1 receptor-associated kinase 1 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of IRAK1 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521
|
|
G |
Itga2 |
integrin subunit alpha 2 |
decreases expression |
ISO |
Enalapril results in decreased expression of ITGA2 mRNA |
CTD |
PMID:25037058 |
|
NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Cyclosporine results in increased expression of KDR mRNA] |
CTD |
PMID:12110003 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kng2 |
kininogen 2 |
increases response to substance |
EXP |
Enalapril results in increased susceptibility to KNG1 protein modified form |
CTD |
PMID:18190998 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB1 mRNA] |
CTD |
PMID:9175058 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamb2 |
laminin subunit beta 2 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Puromycin Aminonucleoside results in increased expression of LAMB2 mRNA] |
CTD |
PMID:9175058 |
|
NCBI chr 8:109,178,367...109,190,552
Ensembl chr 8:109,178,409...109,190,549
|
|
G |
Lep |
leptin |
increases response to substance |
ISO |
LEP protein results in increased susceptibility to Enalapril |
CTD |
PMID:20614101 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
increases expression increases phosphorylation |
EXP |
Enalapril results in increased expression of MAPK9 mRNA; Enalapril results in increased expression of MAPK9 protein Enalapril results in increased phosphorylation of MAPK9 protein |
CTD |
PMID:15531746 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mir146a |
microRNA 146a |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146A |
CTD |
PMID:20524934 |
|
NCBI chr10:27,848,516...27,848,610
Ensembl chr10:27,848,516...27,848,610
|
|
G |
Mir146b |
microRNA 146b |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of MIR146B |
CTD |
PMID:20524934 |
|
NCBI chr 1:245,203,438...245,203,525
Ensembl chr 1:245,203,438...245,203,525
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
decreases expression |
ISO |
Enalapril results in decreased expression of MMP3 mRNA |
CTD |
PMID:25037058 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased activity of MPO protein] |
CTD |
PMID:19114890 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Streptozocin results in decreased expression of MYH6 mRNA]; Enalapril inhibits the reaction [Streptozocin results in decreased expression of MYH6 protein] |
CTD |
PMID:15362513 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
decreases expression multiple interactions |
EXP |
Enalapril results in decreased expression of MYH7 mRNA Enalapril inhibits the reaction [Streptozocin results in increased expression of MYH7 mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of MYH7 protein] |
CTD |
PMID:15362513 PMID:21423293 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Ndst1 |
N-deacetylase and N-sulfotransferase 1 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Streptozocin results in decreased expression of NDST1 protein] |
CTD |
PMID:15793251 |
|
NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression |
EXP |
Enalapril results in decreased expression of NFE2L2 mRNA |
CTD |
PMID:18765277 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases activity multiple interactions |
EXP |
Enalapril results in decreased activity of NFKB1 protein Enalapril inhibits the reaction [Acrolein results in increased expression of NFKB1 mRNA]; Enalapril inhibits the reaction [Acrolein results in increased expression of NFKB1 protein] |
CTD |
PMID:19225048 PMID:21265102 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased degradation of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:19114890 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Noa1 |
nitric oxide associated 1 |
increases expression increases activity |
EXP |
Enalapril results in increased expression of NOA1 mRNA Enalapril results in increased activity of NOA1 protein |
CTD |
PMID:14588141 |
|
NCBI chr14:30,835,012...30,851,296
Ensembl chr14:30,835,247...30,851,293
|
|
G |
Nos2 |
nitric oxide synthase 2 |
decreases expression multiple interactions |
ISO EXP |
Enalapril results in decreased expression of NOS2 protein [paricalcitol co-treated with Enalapril] results in decreased expression of NOS2 protein |
CTD |
PMID:20720404 PMID:21377515 PMID:25037058 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions increases expression affects expression |
EXP ISO |
[Enalapril co-treated with eplerenone] results in decreased expression of NOS3 mRNA; Enalapril inhibits the reaction [Nitric Oxide deficiency results in decreased expression of NOS3 protein] [paricalcitol co-treated with Enalapril] results in increased expression of NOS3 protein; Enalapril inhibits the reaction [Dexamethasone results in decreased expression of NOS3 protein]; Enalapril inhibits the reaction [diisononyl phthalate promotes the reaction [Dexamethasone results in decreased expression of NOS3 protein]] Enalapril results in increased expression of NOS3 protein Enalapril affects the expression of NOS3 mRNA |
CTD |
PMID:12176110 PMID:16197366 PMID:20571278 PMID:20720404 PMID:25037058 PMID:30940551 More...
|
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nppa |
natriuretic peptide A |
decreases expression |
ISO EXP |
Enalapril results in decreased expression of NPPA protein Enalapril results in decreased expression of NPPA mRNA |
CTD |
PMID:2136812 PMID:8112904 PMID:21423293 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Isoproterenol results in increased expression of NPPB protein] |
CTD |
PMID:18806606 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nr3c2 |
nuclear receptor subfamily 3, group C, member 2 |
increases expression |
EXP |
Enalapril results in increased expression of NR3C2 mRNA |
CTD |
PMID:18796534 |
|
NCBI chr19:30,715,648...31,059,885
Ensembl chr19:30,715,648...31,059,885
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
increases expression |
EXP |
Enalapril results in increased expression of NRF1 mRNA |
CTD |
PMID:18765277 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Pdpn |
podoplanin |
increases expression |
EXP |
Enalapril results in increased expression of PDPN protein |
CTD |
PMID:20933085 |
|
NCBI chr 5:155,601,691...155,635,656
Ensembl chr 5:155,601,691...155,635,656
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
[Enalapril co-treated with Glucose] binds to PPARA protein; Enalapril inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]] |
CTD |
PMID:18812576 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression multiple interactions |
EXP |
Enalapril results in decreased expression of PPARG protein Enalapril inhibits the reaction [Isoproterenol results in decreased expression of PPARG protein] |
CTD |
PMID:19225048 PMID:30623541 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
EXP |
Enalapril results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18765277 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
increases expression |
ISO |
Enalapril results in increased expression of PRKAA1 protein |
CTD |
PMID:25037058 |
|
NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978
|
|
G |
Prkca |
protein kinase C, alpha |
decreases expression |
EXP |
Enalapril results in decreased expression of PRKCA protein modified form |
CTD |
PMID:21565836 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
decreases expression |
ISO |
Enalapril results in decreased expression of PTGS1 mRNA |
CTD |
PMID:25037058 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
decreases expression multiple interactions |
EXP ISO |
Enalapril results in decreased expression of PTGS2 protein [paricalcitol co-treated with Enalapril] results in decreased expression of PTGS2 protein |
CTD |
PMID:20720404 PMID:21377515 PMID:25037058 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Folic Acid results in decreased expression of PTH1R protein] |
CTD |
PMID:15728788 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Folic Acid results in increased expression of PTHLH mRNA]; Enalapril inhibits the reaction [Folic Acid results in increased expression of PTHLH protein] |
CTD |
PMID:15728788 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Isoproterenol results in increased expression of RELA protein] |
CTD |
PMID:30623541 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions increases expression increases secretion decreases activity increases activity |
ISO EXP |
[Indomethacin co-treated with Enalapril] results in decreased expression of REN protein; Enalapril inhibits the reaction [[AGT co-treated with REN] results in increased abundance of Aldosterone] Enalapril results in increased expression of REN mRNA; Enalapril results in increased expression of REN protein Enalapril results in increased secretion of REN protein [Sodium Chloride deficiency co-treated with Enalapril] results in increased expression of REN mRNA; GJA5 affects the reaction [Enalapril results in increased secretion of REN protein]; GJC1 affects the reaction [Enalapril results in increased secretion of REN protein]; REN enhancer mutant form results in decreased susceptibility to [Sodium Chloride deficiency co-treated with Enalapril]; Sodium inhibits the reaction [Enalapril results in increased expression of REN mRNA]; Sodium inhibits the reaction [Enalapril results in increased expression of REN protein]; Sodium inhibits the reaction [Enalapril results in increased secretion of REN protein] Enalapril results in decreased activity of REN protein Enalapril results in increased activity of REN protein |
CTD |
PMID:1330361 PMID:2994932 PMID:6094050 PMID:11078175 PMID:12434137 PMID:17846348 PMID:18679781 PMID:18796534 PMID:19109587 PMID:19536436 PMID:19767874 PMID:21423293 PMID:21424707 More...
|
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Corticosterone results in decreased expression of RUNX2 mRNA]; Enalapril inhibits the reaction [Ethanol results in decreased expression of RUNX2 mRNA] |
CTD |
PMID:30423288 PMID:31887396 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sele |
selectin E |
multiple interactions |
ISO |
Enalapril inhibits the reaction [sodium arsenite results in increased expression of SELE protein] |
CTD |
PMID:28973481 |
|
NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741
|
|
G |
Sell |
selectin L |
multiple interactions |
ISO |
[Enalapril co-treated with paricalcitol] results in decreased expression of SELL mRNA |
CTD |
PMID:25037058 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Selp |
selectin P |
multiple interactions decreases expression |
EXP ISO |
Enalapril inhibits the reaction [Diclofenac results in decreased expression of SELP protein] Enalapril results in decreased expression of SELP mRNA |
CTD |
PMID:14716214 PMID:25037058 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpinb2 |
serpin family B member 2 |
decreases expression |
ISO |
Enalapril results in decreased expression of SERPINB2 mRNA |
CTD |
PMID:25037058 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions decreases expression |
EXP |
[eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; [eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein]; [eplerenone co-treated with Enalapril] results in decreased expression of SERPINE1 mRNA; [eplerenone co-treated with Enalapril] results in decreased expression of SERPINE1 protein; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 mRNA]; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased expression of SERPINE1 protein] Enalapril results in decreased expression of SERPINE1 mRNA; Enalapril results in decreased expression of SERPINE1 protein |
CTD |
PMID:18682491 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc15a2 |
solute carrier family 15 member 2 |
multiple interactions |
ISO |
Enalapril inhibits the reaction [SLC15A2 protein results in increased uptake of glycylsarcosine] |
CTD |
PMID:18713951 |
|
NCBI chr11:64,014,182...64,043,228
Ensembl chr11:64,014,182...64,043,225
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
multiple interactions |
ISO |
Enalapril inhibits the reaction [SLC22A12 protein results in increased uptake of Uric Acid] |
CTD |
PMID:21272127 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
multiple interactions |
ISO |
Enalapril inhibits the reaction [SLC22A7 protein results in increased uptake of Glutarates] |
CTD |
PMID:12065749 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc22a8 |
solute carrier family 22 member 8 |
multiple interactions |
ISO |
Enalapril inhibits the reaction [SLC22A8 protein results in increased uptake of p-Aminohippuric Acid] |
CTD |
PMID:15100168 |
|
NCBI chr 1:205,496,331...205,516,378
Ensembl chr 1:205,498,084...205,517,450
|
|
G |
Smad2 |
SMAD family member 2 |
multiple interactions |
EXP |
Enalapril promotes the reaction [paricalcitol results in decreased phosphorylation of SMAD2 protein] |
CTD |
PMID:17513326 |
|
NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323
|
|
G |
Smad7 |
SMAD family member 7 |
increases expression |
EXP |
Enalapril results in increased expression of SMAD7 mRNA; Enalapril results in increased expression of SMAD7 protein |
CTD |
PMID:19197123 PMID:19349682 |
|
NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765
|
|
G |
Sod1 |
superoxide dismutase 1 |
increases expression multiple interactions |
ISO |
Enalapril results in increased expression of SOD1 protein [paricalcitol co-treated with Enalapril] results in increased expression of SOD1 protein |
CTD |
PMID:20720404 PMID:25037058 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases activity multiple interactions decreases expression |
EXP ISO |
Enalapril results in decreased activity of SOD2 protein [paricalcitol co-treated with Enalapril] results in decreased expression of SOD2 protein Enalapril results in decreased expression of SOD2 protein |
CTD |
PMID:18765277 PMID:20720404 PMID:25037058 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
ISO EXP |
[Enalapril co-treated with paricalcitol] results in decreased expression of SPP1 mRNA Enalapril inhibits the reaction [Corticosterone results in decreased expression of SPP1 mRNA]; Enalapril inhibits the reaction [Ethanol results in decreased expression of SPP1 mRNA] |
CTD |
PMID:25037058 PMID:30423288 PMID:31887396 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Ssbp1 |
single stranded DNA binding protein 1 |
increases expression |
EXP |
Enalapril results in increased expression of SSBP1 mRNA |
CTD |
PMID:18765277 |
|
NCBI chr 4:69,266,024...69,276,135
Ensembl chr 4:69,266,102...69,276,135
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Streptozocin results in increased expression of STAT3 mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of STAT3 protein] |
CTD |
PMID:19958114 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions |
EXP |
Enalapril inhibits the reaction [Streptozocin results in increased expression of TEK mRNA] |
CTD |
PMID:19958114 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions decreases expression |
EXP |
[eplerenone co-treated with Enalapril] inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; [eplerenone co-treated with Enalapril] inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; [eplerenone co-treated with Enalapril] results in decreased expression of TGFB1 mRNA; [eplerenone co-treated with Enalapril] results in decreased expression of TGFB1 protein; Enalapril inhibits the reaction [[Aldosterone co-treated with Glucose] results in increased secretion of TGFB1 protein]; Enalapril inhibits the reaction [Aldosterone promotes the reaction [Glucose results in increased expression of TGFB1 mRNA]]; Enalapril inhibits the reaction [Streptozocin results in increased expression of TGFB1 mRNA]; Enalapril inhibits the reaction [Streptozocin results in increased expression of TGFB1 protein]; Enalapril promotes the reaction [paricalcitol results in decreased expression of TGFB1 mRNA]; Enalapril promotes the reaction [paricalcitol results in decreased expression of TGFB1 protein] Enalapril results in decreased expression of TGFB1 mRNA; Enalapril results in decreased expression of TGFB1 protein |
CTD |
PMID:12883979 PMID:15309289 PMID:17164399 PMID:17513326 PMID:18682491 PMID:19197123 PMID:19349682 PMID:23733546 More...
|
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tgfb2 |
transforming growth factor, beta 2 |
decreases expression |
EXP |
Enalapril results in decreased expression of TGFB2 mRNA |
CTD |
PMID:17164399 |
|
NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405
|
|
G |
Tgfbi |
transforming growth factor, beta induced |
decreases secretion multiple interactions |
EXP |
Enalapril results in decreased secretion of TGFBI protein [eplerenone co-treated with Enalapril] results in decreased secretion of TGFBI protein |
CTD |
PMID:18682491 |
|
NCBI chr17:7,955,603...7,984,903
Ensembl chr17:7,955,603...7,985,240
|
|
G |
Tgfbr1 |
transforming growth factor, beta receptor 1 |
decreases expression |
EXP |
Enalapril results in decreased expression of TGFBR1 mRNA; Enalapril results in decreased expression of TGFBR1 protein |
CTD |
PMID:12883979 |
|
NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777
|
|
G |
Thbs4 |
thrombospondin 4 |
increases expression |
ISO |
Enalapril results in increased expression of THBS4 mRNA |
CTD |
PMID:25037058 |
|
NCBI chr 2:23,983,158...24,025,289
Ensembl chr 2:23,983,158...24,026,313
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 mRNA; [Atorvastatin co-treated with Enalapril] results in decreased expression of TLR4 protein |
CTD |
PMID:20524934 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
EXP ISO |
Enalapril results in decreased expression of TNF protein Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased expression of TNF protein]; Enalapril inhibits the reaction [Isoproterenol results in increased expression of TNF protein]; Enalapril inhibits the reaction [Streptozocin results in increased expression of TNF mRNA] [paricalcitol co-treated with Enalapril] results in decreased expression of TNF protein; Enalapril inhibits the reaction [Bleomycin results in increased expression of TNF mRNA]; Enalapril inhibits the reaction [endotoxin, Escherichia coli results in increased secretion of TNF protein] Enalapril inhibits the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]; Enalapril inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; Enalapril inhibits the reaction [TNF protein results in increased expression of VEGFA protein] |
CTD |
PMID:12003776 PMID:16336586 PMID:17167242 PMID:17299153 PMID:18060435 PMID:19114890 PMID:19225048 PMID:20720404 PMID:25037058 PMID:30623541 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
decreases expression |
EXP |
Enalapril results in decreased expression of TOMM20 mRNA |
CTD |
PMID:18765277 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Atorvastatin co-treated with Enalapril] results in decreased expression of TRAF6 mRNA |
CTD |
PMID:20524934 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
affects expression decreases expression |
ISO |
Enalapril affects the expression of VCAM1 Enalapril results in decreased expression of VCAM1 mRNA; Enalapril results in decreased expression of VCAM1 protein modified form |
CTD |
PMID:17347482 PMID:19939336 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
EXP ISO |
Enalapril inhibits the reaction [Cyclosporine results in increased expression of VEGFA protein] Enalapril inhibits the reaction [IL1A protein results in increased expression of VEGFA mRNA]; Enalapril inhibits the reaction [IL1A protein results in increased expression of VEGFA protein]; Enalapril inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; Enalapril inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Enalapril inhibits the reaction [VEGFA protein results in increased expression of VEGFA mRNA] Enalapril results in increased expression of VEGFA protein |
CTD |
PMID:12110003 PMID:16202860 PMID:17299153 PMID:21263376 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vwf |
von Willebrand factor |
decreases expression |
ISO |
Enalapril results in decreased expression of VWF mRNA |
CTD |
PMID:25037058 |
|
NCBI chr 4:158,360,152...158,491,539
Ensembl chr 4:158,360,152...158,491,539
|
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
fumagillin inhibits the reaction [Diethylnitrosamine results in increased expression of BCL2 mRNA] |
CTD |
PMID:15682466 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Metap1 |
methionyl aminopeptidase 1 |
decreases activity multiple interactions |
ISO |
fumagillin results in decreased activity of METAP1 protein [fumagillin results in decreased activity of [METAP1 protein co-treated with METAP2 protein]] which results in decreased metabolism of YWHAG protein |
CTD |
PMID:14534293 |
|
NCBI chr 2:226,991,305...227,024,360
Ensembl chr 2:226,991,301...227,024,434
|
|
G |
Metap2 |
methionyl aminopeptidase 2 |
multiple interactions decreases activity |
EXP ISO |
fumagillin promotes the reaction [Diethylnitrosamine results in increased expression of METAP2 mRNA] fumagillin results in decreased activity of METAP2 protein [fumagillin results in decreased activity of [METAP1 protein co-treated with METAP2 protein]] which results in decreased metabolism of YWHAG protein |
CTD |
PMID:14534293 PMID:15516829 PMID:15682466 |
|
NCBI chr 7:28,412,771...28,440,458
Ensembl chr 7:28,411,608...28,440,434
|
|
G |
Tert |
telomerase reverse transcriptase |
multiple interactions |
EXP |
fumagillin inhibits the reaction [Diethylnitrosamine results in increased activity of TERT protein]; fumagillin inhibits the reaction [Diethylnitrosamine results in increased expression of TERT mRNA] |
CTD |
PMID:15682466 |
|
NCBI chr 1:29,637,213...29,659,509
Ensembl chr 1:29,637,506...29,659,561
|
|
G |
Ywhag |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma |
multiple interactions |
ISO |
[fumagillin results in decreased activity of [METAP1 protein co-treated with METAP2 protein]] which results in decreased metabolism of YWHAG protein |
CTD |
PMID:14534293 |
|
NCBI chr12:20,744,500...20,772,828
Ensembl chr12:20,744,535...20,772,827
|
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[hydrocortisone hemisuccinate co-treated with Dimethyl Sulfoxide] results in increased expression of CYP1A2 |
CTD |
PMID:18347083 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
[hydrocortisone hemisuccinate co-treated with Dimethyl Sulfoxide] results in increased expression of CYP3A4 |
CTD |
PMID:18347083 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
F2 |
coagulation factor II |
affects expression |
ISO |
hydrocortisone hemisuccinate affects the expression of F2 protein |
CTD |
PMID:12542493 |
|
NCBI chr 3:77,596,196...77,609,486
Ensembl chr 3:77,596,198...77,609,486
|
|
G |
Il18 |
interleukin 18 |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of IL18 protein |
CTD |
PMID:20421217 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of IL1B protein |
CTD |
PMID:20421217 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of IL6 protein |
CTD |
PMID:20421217 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Tnf |
tumor necrosis factor |
decreases secretion |
ISO |
hydrocortisone hemisuccinate results in decreased secretion of TNF protein |
CTD |
PMID:20421217 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
increases response to substance |
ISO |
ACE2 gene SNP results in increased susceptibility to imidapril |
CTD |
PMID:27121444 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Ces1d |
carboxylesterase 1D |
multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of and results in increased activity of imidapril; CES1 protein results in increased metabolism of and results in increased activity of imidapril; Dust inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; tert-butylphenyl diphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril]; triphenyl phosphate inhibits the reaction [CES1 protein results in increased metabolism of and results in increased activity of imidapril] |
CTD |
PMID:9300133 PMID:31268531 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Cyp11b3 |
cytochrome P450, family 11, subfamily b, polypeptide 3 |
affects response to substance |
ISO |
CYP11B2 gene polymorphism affects the susceptibility to imidapril |
CTD |
PMID:16765146 |
|
NCBI chr 7:106,808,559...106,814,048
Ensembl chr 7:106,808,559...106,814,048
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein] |
CTD |
PMID:16257180 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions |
ISO |
imidaprilat inhibits the reaction [AGT protein results in increased activity of and results in increased localization of PRKCA protein] |
CTD |
PMID:16257180 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions increases hydrolysis |
EXP |
Dexamethasone promotes the reaction [CES2 protein results in increased hydrolysis of Methylprednisolone Hemisuccinate] |
CTD |
PMID:15794950 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
|
G |
Adam33 |
ADAM metallopeptidase domain 33 |
multiple interactions |
ISO |
[[Endocrine Disruptors results in increased abundance of mono(2-ethyl-5-hydroxyhexyl) phthalate] which results in increased methylation of ADAM33 intron] which results in increased expression of ADAM33 mRNA |
CTD |
PMID:30226539 |
|
NCBI chr 3:118,262,395...118,283,461
Ensembl chr 3:118,271,029...118,283,461
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
mono(2-ethyl-5-hydroxyhexyl) phthalate results in decreased expression of CRP protein |
CTD |
PMID:21349512 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO EXP |
[CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate [CYP2C6V1 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate |
CTD |
PMID:22186153 PMID:23545481 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP ISO |
[CYP3A2 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate [CYP3A4 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate |
CTD |
PMID:23545481 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to Diethylhexyl Phthalate] which affects the abundance of mono(2-ethyl-5-hydroxyhexyl) phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Mirlet7c1 |
microRNA let-7c-1 |
multiple interactions |
ISO |
[Diethylhexyl Phthalate results in increased abundance of mono(2-ethyl-5-hydroxyhexyl) phthalate] which affects the expression of MIRLET7C |
CTD |
PMID:30481674 |
|
NCBI chr11:16,201,163...16,201,256
Ensembl chr11:16,201,158...16,201,265
|
|
G |
Shbg |
sex hormone binding globulin |
decreases secretion |
ISO |
mono(2-ethyl-5-hydroxyhexyl) phthalate results in decreased secretion of SHBG protein |
CTD |
PMID:24945889 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Tug1 |
taurine up-regulated 1 |
affects expression |
ISO |
mono(2-ethyl-5-hydroxyhexyl) phthalate affects the expression of TUG1 mRNA |
CTD |
PMID:29385630 |
|
NCBI chr14:78,519,894...78,526,927
Ensembl chr14:78,522,506...78,526,927
|
|
|
G |
Acin1 |
apoptotic chromatin condensation inducer 1 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of ACIN1 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr15:28,102,112...28,147,001
Ensembl chr15:28,102,112...28,147,001
|
|
G |
Adam33 |
ADAM metallopeptidase domain 33 |
multiple interactions |
ISO |
[[Endocrine Disruptors results in increased abundance of mono(2-ethyl-5-oxohexyl)phthalate] which results in increased methylation of ADAM33 intron] which results in increased expression of ADAM33 mRNA |
CTD |
PMID:30226539 |
|
NCBI chr 3:118,262,395...118,283,461
Ensembl chr 3:118,271,029...118,283,461
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of ANKRD10 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr16:77,866,489...77,889,745
Ensembl chr16:77,864,261...77,889,745
|
|
G |
Ap1g2 |
adaptor related protein complex 1 subunit gamma 2 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of AP1G2 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr15:28,571,571...28,579,421
Ensembl chr15:28,571,568...28,589,004
|
|
G |
Arglu1 |
arginine and glutamate rich 1 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of ARGLU1 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr16:80,753,300...80,777,350
Ensembl chr16:80,753,315...80,777,349
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate results in decreased expression of CCL2 mRNA |
CTD |
PMID:32015430 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccnl1 |
cyclin L1 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of CCNL1 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr 2:150,184,865...150,199,524
Ensembl chr 2:150,184,798...150,197,368
|
|
G |
Cd68 |
Cd68 molecule |
decreases expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate results in decreased expression of CD68 mRNA |
CTD |
PMID:32015430 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Clk1 |
CDC-like kinase 1 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of CLK1 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr 9:59,947,774...59,959,002
Ensembl chr 9:59,947,764...59,957,000
|
|
G |
Crp |
C-reactive protein |
decreases expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate results in decreased expression of CRP mRNA; mono(2-ethyl-5-oxohexyl)phthalate results in decreased expression of CRP protein |
CTD |
PMID:21349512 PMID:32015430 |
|
NCBI chr13:85,131,635...85,175,179
Ensembl chr13:85,124,977...85,175,178
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions |
ISO EXP |
[CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate [CYP2C6V1 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate |
CTD |
PMID:22186153 PMID:23545481 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions |
EXP ISO |
[CYP3A2 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate [CYP3A4 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate |
CTD |
PMID:23545481 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Flg |
filaggrin |
multiple interactions |
ISO |
[FLG gene polymorphism affects the susceptibility to Diethylhexyl Phthalate] which affects the abundance of mono(2-ethyl-5-oxohexyl)phthalate |
CTD |
PMID:24380925 |
|
NCBI chr 2:178,888,688...178,912,731
|
|
G |
Leng8 |
leukocyte receptor cluster member 8 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of LENG8 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr 1:70,040,785...70,052,662
Ensembl chr 1:70,040,785...70,052,488
|
|
G |
Luc7l3 |
LUC7-like 3 pre-mRNA splicing factor |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of LUC7L3 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538
|
|
G |
Mirlet7c1 |
microRNA let-7c-1 |
multiple interactions |
ISO |
[Diethylhexyl Phthalate results in increased abundance of mono(2-ethyl-5-oxohexyl)phthalate] which affects the expression of MIRLET7C |
CTD |
PMID:30481674 |
|
NCBI chr11:16,201,163...16,201,256
Ensembl chr11:16,201,158...16,201,265
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases activity |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate results in increased activity of PPARA protein |
CTD |
PMID:28571686 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate binds to and affects the folding of and results in increased activity of PPARG protein |
CTD |
PMID:30085373 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Rbm6 |
RNA binding motif protein 6 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of RBM6 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr 8:108,452,687...108,552,783
Ensembl chr 8:108,452,687...108,552,771
|
|
G |
Shbg |
sex hormone binding globulin |
decreases secretion |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate results in decreased secretion of SHBG protein |
CTD |
PMID:24945889 |
|
NCBI chr10:54,332,939...54,350,409
Ensembl chr10:54,332,941...54,351,057
|
|
G |
Son |
SON DNA and RNA binding protein |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of SON mRNA |
CTD |
PMID:34478338 |
|
NCBI chr11:30,850,890...30,923,167
Ensembl chr11:30,892,005...30,923,167
|
|
G |
Srsf11 |
serine and arginine rich splicing factor 11 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of SRSF11 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr 2:247,074,623...247,101,460
Ensembl chr 2:247,074,631...247,101,425
|
|
G |
Tubgcp6 |
tubulin, gamma complex associated protein 6 |
affects expression |
ISO |
mono(2-ethyl-5-oxohexyl)phthalate affects the expression of TUBGCP6 mRNA |
CTD |
PMID:34478338 |
|
NCBI chr 7:120,177,686...120,198,986
Ensembl chr 7:120,177,686...120,199,011
|
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ABCA12 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:72,822,661...72,995,748
Ensembl chr 9:72,823,350...72,996,049
|
|
G |
Abca4 |
ATP binding cassette subfamily A member 4 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ABCA4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:210,164,813...210,302,069
Ensembl chr 2:210,164,813...210,302,069
|
|
G |
Abca7 |
ATP binding cassette subfamily A member 7 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ABCA7 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 7:9,691,452...9,711,466
Ensembl chr 7:9,691,449...9,711,425
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ABCB1B mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcb9 |
ATP binding cassette subfamily B member 9 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ABCB9 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr12:32,499,225...32,531,932
Ensembl chr12:32,499,225...32,531,931
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ABCC10 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of ABCC2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ABCC6 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Acaa1b |
acetyl-Coenzyme A acyltransferase 1B |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ACAA1B mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825
|
|
G |
Acaa2 |
acetyl-CoA acyltransferase 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ACAA2 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249
|
|
G |
Acadm |
acyl-CoA dehydrogenase medium chain |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ACADM mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of ACADS mRNA |
CTD |
PMID:22087261 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Acap1 |
ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ACAP1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr10:54,605,323...54,619,472
Ensembl chr10:54,605,323...54,619,472
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
increases expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ACOX1 mRNA |
CTD |
PMID:22087261 PMID:32522588 |
|
NCBI chr10:101,406,197...101,431,242
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Acoxl |
acyl-CoA oxidase-like |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ACOXL mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:115,061,045...115,367,032
Ensembl chr 3:115,061,060...115,364,686
|
|
G |
Acsl1 |
acyl-CoA synthetase long-chain family member 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ACSL1 protein |
CTD |
PMID:27384973 |
|
NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541
|
|
G |
Acsl4 |
acyl-CoA synthetase long-chain family member 4 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ACSL4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADAM22 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962
|
|
G |
Adam23 |
ADAM metallopeptidase domain 23 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADAM23 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:64,862,878...65,006,515
Ensembl chr 9:64,862,878...65,006,515
|
|
G |
Adamts20 |
ADAM metallopeptidase with thrombospondin type 1 motif, 20 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ADAMTS20 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 7:125,396,227...125,528,020
Ensembl chr 7:125,397,734...125,527,777
|
|
G |
Adamts4 |
ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADAMTS4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr13:83,670,556...83,680,045
Ensembl chr13:83,670,183...83,680,065
|
|
G |
Adarb2 |
adenosine deaminase, RNA-specific, B2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADARB2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr17:61,750,437...62,300,984
Ensembl chr17:61,756,067...62,300,831
|
|
G |
Adcy4 |
adenylate cyclase 4 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADCY4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr15:29,266,280...29,282,153
Ensembl chr15:29,266,287...29,282,108
|
|
G |
Adcy7 |
adenylate cyclase 7 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADCY7 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr19:18,740,875...18,798,924
Ensembl chr19:18,740,875...18,776,311
|
|
G |
Adgre4 |
adhesion G protein-coupled receptor E4 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADGRE4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:9,758,106...9,901,908
Ensembl chr 9:9,760,355...9,900,760
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ADIPOQ protein |
CTD |
PMID:27384973 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adipor2 |
adiponectin receptor 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ADIPOR2 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 4:152,524,604...152,588,848
Ensembl chr 4:152,524,623...152,559,355
|
|
G |
Adora1 |
adenosine A1 receptor |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADORA1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Adra1d |
adrenoceptor alpha 1D |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ADRA1D mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354
|
|
G |
Afm |
afamin |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AFM mRNA |
CTD |
PMID:22401849 |
|
NCBI chr14:17,531,026...17,563,868
Ensembl chr14:17,531,024...17,563,870
|
|
G |
Agbl3 |
AGBL carboxypeptidase 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AGBL3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:63,448,789...63,535,538
Ensembl chr 4:63,453,940...63,531,188
|
|
G |
Agl |
amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase |
multiple interactions |
EXP |
mono-(2-ethylhexyl)phthalate binds to and affects the activity of AGL protein |
CTD |
PMID:19240039 |
|
NCBI chr 2:204,705,053...204,760,966
Ensembl chr 2:204,705,053...204,760,828
|
|
G |
Agtr1b |
angiotensin II receptor, type 1b |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of AGTR1B mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:102,844,969...102,920,232
Ensembl chr 2:102,844,969...102,920,232
|
|
G |
Ahcy |
adenosylhomocysteinase |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of AHCY mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression affects expression multiple interactions |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AHR mRNA mono-(2-ethylhexyl)phthalate affects the expression of AHR mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of AHR mRNA |
CTD |
PMID:12706301 PMID:28381288 PMID:31884101 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Ahrr |
aryl-hydrocarbon receptor repressor |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of AHRR mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:28,993,634...29,088,673
Ensembl chr 1:28,993,634...29,088,673
|
|
G |
Ahsg |
alpha-2-HS-glycoprotein |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AHSG protein |
CTD |
PMID:27384973 |
|
NCBI chr11:78,117,903...78,145,956
Ensembl chr11:78,117,918...78,145,999
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AIFM1 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of AIFM1 mRNA; Estradiol affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of AIFM1 mRNA] |
CTD |
PMID:24412242 PMID:31884101 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Aifm3 |
apoptosis inducing factor, mitochondria associated 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AIFM3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr11:83,504,859...83,523,630
Ensembl chr11:83,504,861...83,521,248
|
|
G |
Ajuba |
ajuba LIM protein |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of AJUBA mRNA |
CTD |
PMID:16809437 |
|
NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions increases phosphorylation increases activity affects response to substance |
ISO EXP |
AKT1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 mRNA]; AKT1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 protein]; AKT1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of NFKB1 mRNA]; mono-(2-ethylhexyl)phthalate inhibits the reaction [INS protein results in increased expression of and results in increased phosphorylation of AKT1 protein] [bisphenol A co-treated with mono-(2-ethylhexyl)phthalate] results in increased phosphorylation of AKT1 protein; HDAC6 protein affects the reaction [[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate] results in increased phosphorylation of AKT1 protein] mono-(2-ethylhexyl)phthalate inhibits the reaction [INS1 protein results in increased phosphorylation of AKT1 protein] mono-(2-ethylhexyl)phthalate results in increased phosphorylation of AKT1 protein mono-(2-ethylhexyl)phthalate results in increased activity of AKT1 protein AKT1 protein affects the susceptibility to mono-(2-ethylhexyl)phthalate |
CTD |
PMID:18755736 PMID:28526321 PMID:31009676 PMID:34910997 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of AKT1S1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate analog results in decreased expression of ALPL protein; mono-(2-ethylhexyl)phthalate results in decreased expression of ALPL protein |
CTD |
PMID:25777084 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Amh |
anti-Mullerian hormone |
decreases expression |
ISO EXP |
mono-(2-ethylhexyl)phthalate results in decreased expression of AMH mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of AMH protein |
CTD |
PMID:19165384 PMID:19440488 |
|
NCBI chr 7:8,906,776...8,909,184
Ensembl chr 7:8,906,836...8,909,282
|
|
G |
Ank1 |
ankyrin 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ANK1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr16:68,876,294...69,054,812
Ensembl chr16:68,877,504...69,054,759
|
|
G |
Ano9 |
anoctamin 9 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ANO9 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:196,208,863...196,230,381
Ensembl chr 1:196,197,341...196,229,900
|
|
G |
Antxr2 |
ANTXR cell adhesion molecule 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ANTXR2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr14:11,542,266...11,682,112
Ensembl chr14:11,541,772...11,682,094
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of AOX1 mRNA |
CTD |
PMID:23360888 |
|
NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770
|
|
G |
Apln |
apelin |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of APLN mRNA |
CTD |
PMID:32522588 |
|
NCBI chr X:127,180,801...127,213,567
Ensembl chr X:127,203,823...127,213,391
|
|
G |
Apoe |
apolipoprotein E |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of APOE mRNA |
CTD |
PMID:22087261 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate inhibits the reaction [cyclopamine results in increased expression of AR] [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of AR mRNA |
CTD |
PMID:26710974 PMID:31884101 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of ARNT mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
EXP |
mono-(2-ethylhexyl)phthalate inhibits the reaction [INS1 protein results in increased expression of ARRB2 protein] |
CTD |
PMID:28526321 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Arrdc3 |
arrestin domain containing 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ARRDC3 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr 2:11,137,443...11,149,978
Ensembl chr 2:11,137,460...11,149,978
|
|
G |
Artn |
artemin |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ARTN mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 5:131,458,596...131,470,193
Ensembl chr 5:131,464,756...131,468,025
|
|
G |
Ascc3 |
activating signal cointegrator 1 complex subunit 3 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ASCC3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr20:53,510,137...53,795,446
Ensembl chr20:53,510,184...53,790,165
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of ATF3 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Atf7ip2 |
activating transcription factor 7 interacting protein 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ATF7IP2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr10:5,403,099...5,445,989
Ensembl chr10:5,403,105...5,446,142
|
|
G |
Atp12a |
ATPase H+/K+ transporting non-gastric alpha2 subunit |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ATP12A mRNA |
CTD |
PMID:22401849 |
|
NCBI chr15:30,443,571...30,468,229
Ensembl chr15:30,443,571...30,468,229
|
|
G |
Atp13a4 |
ATPase 13A4 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ATP13A4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr11:71,222,196...71,359,933
Ensembl chr11:71,226,161...71,359,933
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ATP1A3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Atp6v1c2 |
ATPase H+ transporting V1 subunit C2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ATP6V1C2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 6:40,080,545...40,144,199
Ensembl chr 6:40,080,547...40,120,028
|
|
G |
Atp6v1h |
ATPase H+ transporting V1 subunit H |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of ATP6V1H mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 5:14,379,029...14,484,703
Ensembl chr 5:14,378,257...14,537,962
|
|
G |
Atp8b4 |
ATPase phospholipid transporting 8B4 (putative) |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ATP8B4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:113,554,979...113,757,635
Ensembl chr 3:113,556,192...113,757,225
|
|
G |
Atp9b |
ATPase phospholipid transporting 9B (putative) |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ATP9B mRNA |
CTD |
PMID:22401849 |
|
NCBI chr18:74,176,863...74,368,993
Ensembl chr18:74,176,863...74,368,953
|
|
G |
Atrnl1 |
attractin like 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ATRNL1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:256,670,976...257,219,291
Ensembl chr 1:256,670,627...257,213,197
|
|
G |
Avpi1 |
arginine vasopressin-induced 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of AVPI1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:240,930,236...240,936,154
Ensembl chr 1:240,930,236...240,936,154
|
|
G |
B3galt1 |
Beta-1,3-galactosyltransferase 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of B3GALT1 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 3:52,253,413...52,826,508
Ensembl chr 3:52,253,618...52,825,313
|
|
G |
B3galt2 |
Beta-1,3-galactosyltransferase 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of B3GALT2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr13:55,389,406...55,398,419
Ensembl chr13:55,389,406...55,398,419
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of BAX mRNA; mono-(2-ethylhexyl)phthalate results in increased expression of BAX protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of BAX mRNA |
CTD |
PMID:12927354 PMID:24706461 PMID:26597031 PMID:31884101 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Baz1a |
bromodomain adjacent to zinc finger domain, 1A |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BAZ1A mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 6:72,389,701...72,512,516
Ensembl chr 6:72,389,703...72,512,459
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of BBC3 protein |
CTD |
PMID:24706461 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BCL2 mRNA; mono-(2-ethylhexyl)phthalate results in decreased expression of BCL2 protein MIR16-1 mRNA affects the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of BCL2 protein] [mono-(2-ethylhexyl)phthalate co-treated with Estradiol] results in decreased expression of BCL2 mRNA; [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of BCL2 mRNA |
CTD |
PMID:12927354 PMID:24412242 PMID:24706461 PMID:26597031 PMID:31884101 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
ISO |
AKT1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 mRNA]; AKT1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 protein] mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 mRNA; mono-(2-ethylhexyl)phthalate results in increased expression of BCL2L1 protein |
CTD |
PMID:18755736 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l10 |
Bcl2-like 10 |
multiple interactions decreases expression |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of BCL2L10 mRNA; Estradiol affects the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of BCL2L10 mRNA] |
CTD |
PMID:24412242 PMID:31884101 |
|
NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367
|
|
G |
Bcl6 |
BCL6, transcription repressor |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of BCL6 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr11:76,854,090...76,877,389
Ensembl chr11:76,854,090...76,877,389
|
|
G |
Bean1 |
brain expressed, associated with NEDD4, 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BEAN1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr19:739,551...786,122
Ensembl chr19:739,551...787,537
|
|
G |
Bhmt |
betaine-homocysteine S-methyltransferase |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BHMT mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:24,859,871...24,879,449
Ensembl chr 2:24,859,873...24,879,742
|
|
G |
Bicra |
BRD4 interacting chromatin remodeling complex associated protein |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BICRA mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:76,661,897...76,736,146
Ensembl chr 1:76,661,897...76,737,157
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of BID mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bok |
BCL2 family apoptosis regulator BOK |
decreases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BOK mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of BOK mRNA |
CTD |
PMID:24412242 PMID:31884101 |
|
NCBI chr 9:94,223,493...94,234,476
Ensembl chr 9:94,223,389...94,234,476
|
|
G |
Bpifb6 |
BPI fold containing family B, member 6 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BPIFB6 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:142,383,701...142,395,308
Ensembl chr 3:142,381,374...142,395,308
|
|
G |
Brd3 |
bromodomain containing 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of BRD3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:10,773,163...10,829,675
Ensembl chr 3:10,775,272...10,829,577
|
|
G |
Brsk1 |
BR serine/threonine kinase 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BRSK1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:69,134,166...69,159,947
Ensembl chr 1:69,134,565...69,160,365
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of BTG2 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Bves |
blood vessel epicardial substance |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of BVES mRNA |
CTD |
PMID:22401849 |
|
NCBI chr20:48,819,241...48,860,282
Ensembl chr20:48,822,308...48,857,472
|
|
G |
C1qtnf6 |
C1q and TNF related 6 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of C1QTNF6 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 7:110,077,867...110,084,584
Ensembl chr 7:110,077,878...110,084,412
|
|
G |
C8a |
complement C8 alpha chain |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of C8A mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 5:119,583,168...119,637,675
Ensembl chr 5:119,583,174...119,637,754
|
|
G |
Cabp1 |
calcium binding protein 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CABP1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr12:41,385,234...41,448,930
Ensembl chr12:41,378,897...41,448,927
|
|
G |
Cadm1 |
cell adhesion molecule 1 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CADM1 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833
|
|
G |
Camk1d |
calcium/calmodulin-dependent protein kinase ID |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CAMK1D mRNA |
CTD |
PMID:22401849 |
|
NCBI chr17:72,581,899...72,982,704
Ensembl chr17:72,581,979...72,980,556
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity increases expression |
ISO EXP |
2,2-bis(4-glycidyloxyphenyl)propane inhibits the reaction [PPARG protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CASP3 protein]]; 2-chloro-5-nitrobenzanilide inhibits the reaction [PPARG protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CASP3 protein]]; PPARG protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CASP3 protein]; rosiglitazone promotes the reaction [PPARG protein promotes the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CASP3 protein]] mono-(2-ethylhexyl)phthalate results in increased cleavage of CASP3 protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CASP3 mRNA mono-(2-ethylhexyl)phthalate results in increased expression of CASP3 protein |
CTD |
PMID:12927354 PMID:19165384 PMID:19720108 PMID:23360888 PMID:24706461 PMID:30476341 PMID:31884101 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
mono-(2-ethylhexyl)phthalate results in increased activity of CASP7 protein |
CTD |
PMID:23360888 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CASP8 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
mono-(2-ethylhexyl)phthalate results in increased activity of CASP9 protein |
CTD |
PMID:24706461 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions increases activity increases expression |
EXP ISO |
Cycloheximide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of CAT protein] mono-(2-ethylhexyl)phthalate results in increased activity of CAT protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CAT mRNA |
CTD |
PMID:2306265 PMID:6845354 PMID:31884101 PMID:32522588 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cbr1 |
carbonyl reductase 1 |
multiple interactions |
ISO |
[mono-(2-ethylhexyl)phthalate co-treated with Genistein] results in increased expression of CBR1 mRNA |
CTD |
PMID:34942354 |
|
NCBI chr11:32,860,618...32,862,981
Ensembl chr11:32,908,950...32,911,393 Ensembl chr11:32,908,950...32,911,393
|
|
G |
Cbr1l1 |
carbonyl reductase 1 like 1 |
multiple interactions |
ISO |
[mono-(2-ethylhexyl)phthalate co-treated with Genistein] results in increased expression of CBR1 mRNA |
CTD |
PMID:34942354 |
|
NCBI chr11:32,876,563...32,884,234
|
|
G |
Cbs |
cystathionine beta synthase |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CBS mRNA |
CTD |
PMID:21195148 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccdc27 |
coiled-coil domain containing 27 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CCDC27 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 5:164,585,285...164,599,391
Ensembl chr 5:164,585,267...164,599,355
|
|
G |
Ccdc96 |
coiled-coil domain containing 96 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CCDC96 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CCL2 mRNA |
CTD |
PMID:27384973 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CCN1 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CCN2 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna2 |
cyclin A2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNA2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNB1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNB2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccnd1 |
cyclin D1 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CCND1 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CCND2 mRNA Estradiol inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CCND2 mRNA] |
CTD |
PMID:19874833 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Ccnd3 |
cyclin D3 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCND3 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371
|
|
G |
Ccne1 |
cyclin E1 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CCNE1 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101
|
|
G |
Ccno |
cyclin O |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CCNO mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 2:44,630,640...44,633,914
Ensembl chr 2:44,626,369...44,633,914
|
|
G |
Ccr7 |
C-C motif chemokine receptor 7 |
multiple interactions |
ISO |
[bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of CCR7 mRNA |
CTD |
PMID:30398665 |
|
NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309
|
|
G |
Ccrl2 |
C-C motif chemokine receptor like 2 |
increases expression decreases expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CCRL2 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of CCRL2 mRNA |
CTD |
PMID:16809437 PMID:22401849 |
|
NCBI chr 8:111,034,279...111,036,914
Ensembl chr 8:111,034,279...111,036,664
|
|
G |
Cd109 |
CD109 molecule |
affects expression decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CD109 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of CD109 mRNA |
CTD |
PMID:21195148 PMID:22401849 |
|
NCBI chr 8:79,454,480...79,569,195
Ensembl chr 8:79,454,480...79,569,194
|
|
G |
Cd163 |
CD163 molecule |
increases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CD163 protein [bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in decreased expression of CD163 mRNA mono-(2-ethylhexyl)phthalate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD163 mRNA] |
CTD |
PMID:22143055 PMID:29718165 PMID:30398665 |
|
NCBI chr 4:157,085,080...157,118,470
Ensembl chr 4:157,085,093...157,117,878
|
|
G |
Cd24 |
CD24 molecule |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CD24A mRNA |
CTD |
PMID:21195148 |
|
NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662
|
|
G |
Cd36 |
CD36 molecule |
multiple interactions increases expression |
ISO |
mono-(2-ethylhexyl)phthalate inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased expression of CD36 mRNA] mono-(2-ethylhexyl)phthalate results in increased expression of CD36 mRNA |
CTD |
PMID:29718165 PMID:35421560 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd40 |
CD40 molecule |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CD40 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Cd69 |
Cd69 molecule |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CD69 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
[Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [mono-(2-ethylhexyl)phthalate affects the localization of CDH2 protein]; mono-(2-ethylhexyl)phthalate results in increased expression of and affects the localization of CDH2 protein |
CTD |
PMID:29940330 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdh23 |
cadherin-related 23 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CDH23 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr20:28,240,643...28,622,490
Ensembl chr20:28,240,645...28,622,419
|
|
G |
Cdhr2 |
cadherin-related family member 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CDHR2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr17:9,876,853...9,913,356
Ensembl chr17:9,876,860...9,912,575
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDK2 mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CDK4 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDK4 mRNA; Estradiol inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CDK4 mRNA] |
CTD |
PMID:19874833 PMID:31884101 |
|
NCBI chr 7:62,885,647...62,889,562
Ensembl chr 7:62,883,105...62,942,403
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
decreases expression multiple interactions increases activity |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CDKN1A mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN1A mRNA Selenomethionine inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CDKN1A protein]; Sodium Selenite inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased activity of CDKN1A protein] |
CTD |
PMID:21515331 PMID:22401849 PMID:31884101 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN1B mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN1C mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN2A mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CDKN2B mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CDKN2C mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn2d |
cyclin dependent kinase inhibitor 2D |
multiple interactions |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] affects the expression of CDKN2D mRNA |
CTD |
PMID:31884101 |
|
NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674
|
|
G |
Cdo1 |
cysteine dioxygenase type 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CDO1 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr18:39,432,473...39,447,253
Ensembl chr18:39,432,474...39,447,296
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
decreases expression increases expression multiple interactions |
ISO EXP |
mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein mono-(2-ethylhexyl)phthalate results in increased expression of CEBPA mRNA Colforsin inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CEBPA protein] |
CTD |
PMID:21832167 PMID:25543134 PMID:27384973 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CEBPB mRNA |
CTD |
PMID:25543134 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Celsr2 |
cadherin, EGF LAG seven-pass G-type receptor 2 |
multiple interactions increases phosphorylation affects transport |
ISO |
[IC 261 results in decreased activity of CSNK1A1 protein] inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased phosphorylation of CELSR2 protein] mono-(2-ethylhexyl)phthalate affects the transport of CELSR2 protein |
CTD |
PMID:16484285 |
|
NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
multiple interactions |
ISO |
[FASL affects the susceptibility to mono-(2-ethylhexyl)phthalate] which affects the expression of CFLAR protein |
CTD |
PMID:20100735 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
multiple interactions affects expression increases expression increases secretion |
ISO |
mono-(2-ethylhexyl)phthalate inhibits the reaction [CGA protein results in increased abundance of Estradiol] mono-(2-ethylhexyl)phthalate affects the expression of CGA mRNA mono-(2-ethylhexyl)phthalate results in increased expression of CGA mRNA mono-(2-ethylhexyl)phthalate results in increased secretion of CGA protein mono-(2-ethylhexyl)phthalate inhibits the reaction [CGA protein results in increased abundance of Progesterone] |
CTD |
PMID:19501113 PMID:27181934 PMID:28381288 PMID:29089286 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Chat |
choline O-acetyltransferase |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CHAT mRNA |
CTD |
PMID:21145954 |
|
NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093
|
|
G |
Chd5 |
chromodomain helicase DNA binding protein 5 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CHD5 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 5:162,848,273...162,898,997
Ensembl chr 5:162,848,394...162,896,291
|
|
G |
Chek2 |
checkpoint kinase 2 |
multiple interactions increases phosphorylation |
ISO |
gingerol inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased phosphorylation of CHEK2 protein] |
CTD |
PMID:28988496 |
|
NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286
|
|
G |
Chrd |
chordin |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CHRD mRNA |
CTD |
PMID:21195148 |
|
NCBI chr11:80,171,994...80,181,166
Ensembl chr11:80,171,994...80,180,673
|
|
G |
Chrna9 |
cholinergic receptor nicotinic alpha 9 subunit |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CHRNA9 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr14:42,235,218...42,241,939
Ensembl chr14:42,235,226...42,242,192
|
|
G |
Cidea |
cell death-inducing DFFA-like effector a |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CIDEA mRNA |
CTD |
PMID:32522588 |
|
NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481
|
|
G |
Clasp2 |
cytoplasmic linker associated protein 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CLASP2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 8:113,677,345...113,859,957
Ensembl chr 8:113,677,284...113,858,731
|
|
G |
Cldn18 |
claudin 18 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CLDN18 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 8:100,246,499...100,265,797
Ensembl chr 8:100,247,633...100,273,351
|
|
G |
Cldn6 |
claudin 6 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CLDN6 mRNA |
CTD |
PMID:22321834 |
|
NCBI chr10:12,710,302...12,713,987
Ensembl chr10:12,709,960...12,715,973
|
|
G |
Clstn3 |
calsyntenin 3 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CLSTN3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:157,331,494...157,364,769
Ensembl chr 4:157,331,494...157,364,769
|
|
G |
Cmtm2a |
CKLF-like MARVEL transmembrane domain containing 2A |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CMTM2B mRNA |
CTD |
PMID:22401849 |
|
NCBI chr19:671,719...678,839
Ensembl chr19:671,719...678,837
|
|
G |
Cnga2 |
cyclic nucleotide gated channel subunit alpha 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CNGA2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr X:149,696,999...149,715,051
Ensembl chr X:149,696,997...149,715,051
|
|
G |
Cnga4 |
cyclic nucleotide gated channel subunit alpha 4 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CNGA4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:159,752,357...159,756,369
Ensembl chr 1:159,752,357...159,756,375
|
|
G |
Cntn3 |
contactin 3 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CNTN3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:134,841,268...135,214,460
Ensembl chr 4:134,842,266...135,125,613
|
|
G |
Cntnap5b |
contactin associated protein family member 5B |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CNTNAP5A mRNA |
CTD |
PMID:22401849 |
|
NCBI chr13:17,863,367...18,766,983
Ensembl chr13:18,093,420...18,761,014
|
|
G |
Cntrl |
centriolin |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CNTRL mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 3:18,428,147...18,500,362
Ensembl chr 3:18,428,103...18,500,380
|
|
G |
Col12a1 |
collagen type XII alpha 1 chain |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of COL12A1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 8:80,547,592...80,665,665
Ensembl chr 8:80,547,593...80,665,686
|
|
G |
Col25a1 |
collagen type XXV alpha 1 chain |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of COL25A1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:218,755,152...219,154,348
Ensembl chr 2:218,755,691...219,153,501
|
|
G |
Col2a1 |
collagen type II alpha 1 chain |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of COL2A1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 7:129,098,489...129,127,620
Ensembl chr 7:129,098,786...129,127,546
|
|
G |
Col4a6 |
collagen type IV alpha 6 chain |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of COL4A6 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr X:104,766,463...105,117,499
Ensembl chr X:104,766,957...105,117,500
|
|
G |
Cox7a1 |
cytochrome c oxidase subunit 7A1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of COX7A1 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 1:85,422,162...85,447,530
Ensembl chr 1:85,441,871...85,445,151
|
|
G |
Cpa5 |
carboxypeptidase A5 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CPA5 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:59,229,754...59,249,503
Ensembl chr 4:59,230,964...59,249,490
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression affects expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CPT1A mRNA mono-(2-ethylhexyl)phthalate affects the expression of CPT1A mRNA |
CTD |
PMID:22401849 PMID:32522588 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CPT2 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 5:122,664,677...122,682,126
Ensembl chr 5:122,664,677...122,682,095
|
|
G |
Crhbp |
corticotropin releasing hormone binding protein |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CRHBP mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:26,692,403...26,704,710
Ensembl chr 2:26,692,403...26,704,710
|
|
G |
Crhr2 |
corticotropin releasing hormone receptor 2 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CRHR2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:84,222,897...84,265,924
Ensembl chr 4:84,224,002...84,265,904
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
multiple interactions |
ISO |
[IC 261 results in decreased activity of CSNK1A1 protein] inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased phosphorylation of CELSR2 protein] |
CTD |
PMID:16484285 |
|
NCBI chr18:55,017,049...55,050,184
Ensembl chr18:55,017,055...55,049,271
|
|
G |
Cth |
cystathionine gamma-lyase |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CTH mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 2:246,975,888...247,002,234
Ensembl chr 2:246,975,894...247,002,234
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression multiple interactions |
ISO EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CTNNB1 mRNA [Ascorbic Acid co-treated with Vitamin E] inhibits the reaction [mono-(2-ethylhexyl)phthalate affects the localization of CTNNB1 protein]; mono-(2-ethylhexyl)phthalate results in increased expression of and affects the localization of CTNNB1 protein |
CTD |
PMID:22321834 PMID:29940330 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CTSL mRNA |
CTD |
PMID:16809437 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cubn |
cubilin |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of CUBN mRNA |
CTD |
PMID:22401849 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of CXCL1 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression multiple interactions |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CXCL10 mRNA [bisphenol A co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-benzyl phthalate co-treated with monobutyl phthalate] results in increased expression of CXCL10 mRNA |
CTD |
PMID:16809437 PMID:30398665 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CXCL1 mRNA |
CTD |
PMID:27384973 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyc1 |
cytochrome c-1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CYC1 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479
|
|
G |
Cycs |
cytochrome c, somatic |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of CYCS mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
increases activity increases expression multiple interactions decreases expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased activity of CYP11A1 protein mono-(2-ethylhexyl)phthalate results in increased expression of CYP11A1 mRNA [Genistein co-treated with mono-(2-ethylhexyl)phthalate] results in increased expression of CYP11A1 mRNA; [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP11A1 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of CYP11A1 mRNA; mono-(2-ethylhexyl)phthalate results in decreased expression of CYP11A1 protein |
CTD |
PMID:22401849 PMID:22525294 PMID:27181934 PMID:29089286 PMID:31884101 PMID:34627990 More...
|
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
increases expression multiple interactions decreases expression affects expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CYP17A1 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP17A1 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of CYP17A1 mRNA; mono-(2-ethylhexyl)phthalate results in decreased expression of CYP17A1 protein mono-(2-ethylhexyl)phthalate affects the expression of CYP17A1 |
CTD |
PMID:16809437 PMID:19560483 PMID:22087261 PMID:31884101 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity multiple interactions increases expression decreases expression |
ISO EXP |
mono-(2-ethylhexyl)phthalate results in decreased activity of CYP19A1 protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP19A1 mRNA mono-(2-ethylhexyl)phthalate results in increased expression of CYP19A1 mRNA alitretinoin promotes the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CYP19A1 mRNA] mono-(2-ethylhexyl)phthalate inhibits the reaction [Colforsin results in increased expression of CYP19A1 mRNA] |
CTD |
PMID:12706301 PMID:19501113 PMID:19822197 PMID:19874833 PMID:22401849 PMID:29089286 PMID:31884101 More...
|
|
NCBI chr 8:54,553,165...54,580,758
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression decreases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CYP1A1 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of CYP1A1 mRNA [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in increased expression of CYP1A1 mRNA |
CTD |
PMID:15521013 PMID:31884101 PMID:34954075 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
increases expression decreases expression multiple interactions |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of CYP1B1 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of CYP1B1 mRNA 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [mono-(2-ethylhexyl)phthalate results in decreased expression of CYP1B1 mRNA]; [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of CYP1B1 mRNA |
CTD |
PMID:12706301 PMID:31884101 PMID:34954075 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp2c11 |
cytochrome P450, subfamily 2, polypeptide 11 |
decreases activity |
EXP |
mono-(2-ethylhexyl)phthalate results in decreased activity of CYP2C11 protein |
CTD |
PMID:27432241 |
|
NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
multiple interactions increases metabolic processing |
EXP ISO |
[CYP2C6V1 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate; [CYP2C6V1 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate; [CYP2C6V1 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of phthalic acid [CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate; [CYP2C19 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate |
CTD |
PMID:22186153 PMID:23545481 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[CYP3A2 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate; [CYP3A2 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate; [CYP3A2 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of phthalic acid [CYP3A4 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-hydroxyhexyl) phthalate; [CYP3A4 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of mono(2-ethyl-5-oxohexyl)phthalate; [CYP3A4 protein results in increased metabolism of mono-(2-ethylhexyl)phthalate] which results in increased chemical synthesis of phthalic acid; [Dexamethasone co-treated with mono-(2-ethylhexyl)phthalate] results in increased activity of CYP3A4 protein mono-(2-ethylhexyl)phthalate results in increased expression of CYP3A4 mRNA |
CTD |
PMID:18332045 PMID:22186153 PMID:23545481 PMID:27551952 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
decreases activity |
EXP |
mono-(2-ethylhexyl)phthalate results in decreased activity of CYP3A62 protein |
CTD |
PMID:27432241 |
|
NCBI chr12:16,397,998...16,433,833
Ensembl chr12:16,397,998...16,433,833
|
|
G |
Cyp51 |
cytochrome P450, family 51 |
decreases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in decreased expression of CYP51 mRNA |
CTD |
PMID:22087261 |
|
NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
|
|
G |
Dach1 |
dachshund family transcription factor 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DACH1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr15:74,528,122...74,909,811
Ensembl chr15:74,529,208...74,909,922
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DDIT3 mRNA |
CTD |
PMID:22321834 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx4 |
DEAD-box helicase 4 |
decreases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in decreased expression of DDX4 mRNA |
CTD |
PMID:30476341 |
|
NCBI chr 2:44,227,946...44,282,867
Ensembl chr 2:44,227,946...44,282,723
|
|
G |
Derl3 |
derlin 3 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of DERL3 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr20:12,754,490...12,768,454
Ensembl chr20:12,763,543...12,767,027
|
|
G |
Dgkb |
diacylglycerol kinase, beta |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DGKB mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 6:54,640,948...55,397,210
Ensembl chr 6:54,641,614...55,397,043
|
|
G |
Dhcr24 |
24-dehydrocholesterol reductase |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DHCR24 mRNA |
CTD |
PMID:23360888 |
|
NCBI chr 5:121,344,637...121,368,853
Ensembl chr 5:121,344,575...121,371,137
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects expression decreases expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate affects the expression of DHCR7; mono-(2-ethylhexyl)phthalate affects the expression of DHCR7 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16809437 PMID:19560483 PMID:22401849 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Dhrs4 |
dehydrogenase/reductase 4 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DHRS4 protein |
CTD |
PMID:27384973 |
|
NCBI chr15:28,966,544...28,978,135
Ensembl chr15:28,966,553...28,978,127
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
increases expression decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DIABLO protein mono-(2-ethylhexyl)phthalate results in decreased expression of DIABLO mRNA |
CTD |
PMID:18755736 PMID:24706461 |
|
NCBI chr12:33,055,784...33,070,400
Ensembl chr12:33,055,263...33,070,387
|
|
G |
Dipk2a |
divergent protein kinase domain 2A |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of DIPK2A mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 8:95,070,695...95,089,815
Ensembl chr 8:95,030,279...95,089,815
|
|
G |
Disp3 |
dispatched RND transporter family member 3 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DISP3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 5:158,672,015...158,720,806
Ensembl chr 5:158,672,015...158,720,806
|
|
G |
Dmd |
dystrophin |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DMD mRNA |
CTD |
PMID:22401849 |
|
NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207
|
|
G |
Dmp1 |
dentin matrix acidic phosphoprotein 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DMP1 mRNA |
CTD |
PMID:25777084 |
|
NCBI chr14:5,528,441...5,542,078
Ensembl chr14:5,528,431...5,539,323
|
|
G |
Dnah14 |
dynein axonemal heavy chain 14 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DNAH14 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr13:93,322,653...93,540,706
Ensembl chr13:93,322,711...93,538,646
|
|
G |
Dnah8 |
dynein, axonemal, heavy chain 8 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DNAH8 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr20:8,692,939...8,946,780
Ensembl chr20:8,692,963...8,946,772
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DNAJB1 mRNA |
CTD |
PMID:24356939 |
|
NCBI chr19:24,522,717...24,526,458
Ensembl chr19:24,522,717...24,526,458
|
|
G |
Dnmt1 |
DNA methyltransferase 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DNMT1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659
|
|
G |
Dock10 |
dedicator of cytokinesis 10 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DOCK10 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:81,843,604...82,101,525
|
|
G |
Dock5 |
dedicator of cytokinesis 5 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DOCK5 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr15:41,979,728...42,158,733
Ensembl chr15:41,979,729...42,158,649
|
|
G |
Dpep1 |
dipeptidase 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DPEP1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr19:51,209,831...51,237,004
Ensembl chr19:51,219,660...51,235,257
|
|
G |
Dpep2 |
dipeptidase 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DPEP2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr19:33,883,557...33,896,487
Ensembl chr19:33,885,478...33,891,954
|
|
G |
Dpp6 |
dipeptidyl peptidase like 6 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DPP6 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 4:7,589,386...8,508,666
Ensembl chr 4:7,591,009...8,508,532
|
|
G |
Dpy19l1 |
dpy-19 like C-mannosyltransferase 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DPY19L1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 8:22,933,163...23,021,461
Ensembl chr 8:22,933,163...23,021,751
|
|
G |
Dpysl4 |
dihydropyrimidinase-like 4 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DPYSL4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:193,883,039...193,898,916
Ensembl chr 1:193,883,106...193,898,914
|
|
G |
Dsc2 |
desmocollin 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of DSC2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr18:11,450,392...11,482,476
Ensembl chr18:11,450,390...11,482,392
|
|
G |
Dst |
dystonin |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DST mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:36,135,657...36,529,617
Ensembl chr 9:36,135,284...36,529,615
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression decreases expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of DUSP1 mRNA mono-(2-ethylhexyl)phthalate results in decreased expression of DUSP1 mRNA |
CTD |
PMID:16809437 PMID:22401849 |
|
NCBI chr10:16,680,489...16,683,276
|
|
G |
Dusp5 |
dual specificity phosphatase 5 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of DUSP5 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 1:252,538,408...252,555,320
Ensembl chr 1:252,538,449...252,551,818
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of DUSP6 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 7:34,092,848...34,097,186
Ensembl chr 7:34,092,943...34,097,185
|
|
G |
Ebf3 |
EBF transcription factor 3 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of EBF3 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 1:191,996,726...192,114,713
Ensembl chr 1:191,996,730...192,114,359
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of EBP mRNA |
CTD |
PMID:22087261 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Ech1 |
enoyl-CoA hydratase 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ECH1 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr 1:84,114,494...84,120,788
Ensembl chr 1:84,112,751...84,120,795
|
|
G |
Eci1 |
enoyl-CoA delta isomerase 1 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ECI1 mRNA |
CTD |
PMID:32522588 |
|
NCBI chr10:13,456,715...13,470,061
Ensembl chr10:13,456,563...13,470,061
|
|
G |
Ecm1 |
extracellular matrix protein 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ECM1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:183,287,491...183,292,729
Ensembl chr 2:183,287,322...183,292,671
|
|
G |
Edn1 |
endothelin 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of EDN1 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Efcab10 |
EF-hand calcium binding domain 10 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of EFCAB10 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 6:50,004,479...50,011,398
Ensembl chr 6:50,004,479...50,011,398
|
|
G |
Efhd1 |
EF-hand domain family, member D1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of EFHD1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917
|
|
G |
Efnb2 |
ephrin B2 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of EFNB2 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391
|
|
G |
Egf |
epidermal growth factor |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of EGF mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
EXP ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of EGR1 mRNA |
CTD |
PMID:8764118 PMID:16809437 |
|
NCBI chr18:26,463,333...26,465,531
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Egr3 |
early growth response 3 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of EGR3 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627
|
|
G |
Egr4 |
early growth response 4 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of EGR4 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328
|
|
G |
Eif5b |
eukaryotic translation initiation factor 5B |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of EIF5B mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:40,222,769...40,277,482
Ensembl chr 9:40,222,898...40,277,482
|
|
G |
Elf1 |
E74 like ETS transcription factor 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of ELF1 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr15:54,890,644...54,986,721
Ensembl chr15:54,865,616...54,986,699
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of ENOX1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr15:52,517,833...53,079,752
Ensembl chr15:52,515,178...53,079,749
|
|
G |
Ep300 |
E1A binding protein p300 |
multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate promotes the reaction [PPARA protein binds to EP300 protein] |
CTD |
PMID:20123618 |
|
NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088 Ensembl chr 7:113,106,247...113,136,088
|
|
G |
Epb41l1 |
erythrocyte membrane protein band 4.1-like 1 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of EPB41L1 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 3:144,929,195...145,052,723
Ensembl chr 3:144,984,640...145,052,721
|
|
G |
Epb41l3 |
erythrocyte membrane protein band 4.1-like 3 |
affects expression |
ISO |
mono-(2-ethylhexyl)phthalate affects the expression of EPB41L3 mRNA |
CTD |
PMID:21195148 |
|
NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:109,016,113...109,260,607
|
|
G |
Epdr1 |
ependymin related 1 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of EPDR1 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr17:45,333,677...45,358,597
Ensembl chr17:45,333,956...45,358,594
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of EPHX1 mRNA |
CTD |
PMID:12706301 |
|
NCBI chr13:92,714,315...92,744,124
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of EPHX2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Erbb4 |
erb-b2 receptor tyrosine kinase 4 |
increases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in increased expression of ERBB4 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 9:69,523,733...70,596,743
Ensembl chr 9:69,531,481...70,596,595
|
|
G |
Ern2 |
endoplasmic reticulum to nucleus signaling 2 |
multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate promotes the reaction [INS protein results in increased phosphorylation of ERN2 protein] |
CTD |
PMID:31009676 |
|
NCBI chr 1:176,726,454...176,743,289
Ensembl chr 1:176,726,454...176,743,289
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions affects expression increases expression |
ISO |
[monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of ESR1 mRNA; mono-(2-ethylhexyl)phthalate binds to and results in increased activity of ESR1 protein mono-(2-ethylhexyl)phthalate affects the expression of ESR1 mRNA ESR1 protein affects the reaction [mono-(2-ethylhexyl)phthalate affects the expression of ESR1 mRNA]; ESR1 protein affects the reaction [mono-(2-ethylhexyl)phthalate affects the expression of MMP2 mRNA]; ESR1 protein affects the reaction [mono-(2-ethylhexyl)phthalate affects the expression of MMP9 mRNA]; ESR1 protein affects the reaction [mono-(2-ethylhexyl)phthalate affects the expression of TIMP2 mRNA]; ESR1 protein affects the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of PCNA mRNA]; mono-(2-ethylhexyl)phthalate binds to and results in increased activity of ESR1 protein mono-(2-ethylhexyl)phthalate results in increased expression of ESR1 protein |
CTD |
PMID:20209442 PMID:31884101 PMID:33049310 PMID:33631300 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate binds to and results in increased activity of ESR2 protein [monoethyl phthalate co-treated with mono-(2-ethylhexyl)phthalate co-treated with mono-isobutyl phthalate co-treated with monoisononylphthalate co-treated with mono-benzyl phthalate] results in decreased expression of ESR2 mRNA |
CTD |
PMID:31884101 PMID:33049310 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F10 |
coagulation factor X |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of F10 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr16:76,468,834...76,488,141
Ensembl chr16:76,468,838...76,488,141
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of F3 mRNA |
CTD |
PMID:16809437 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fabp3 |
fatty acid binding protein 3 |
increases expression |
EXP |
mono-(2-ethylhexyl)phthalate results in increased expression of FABP3 mRNA; mono-(2-ethylhexyl)phthalate results in increased expression of FABP3 protein |
CTD |
PMID:12706301 PMID:15647598 |
|
NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718
|
|
G |
Fabp4 |
fatty acid binding protein 4 |
increases expression multiple interactions |
ISO |
mono-(2-ethylhexyl)phthalate analog results in increased expression of FABP4 mRNA; mono-(2-ethylhexyl)phthalate results in increased expression of FABP4 mRNA; mono-(2-ethylhexyl)phthalate results in increased expression of FABP4 protein T 0070907 inhibits the reaction [mono-(2-ethylhexyl)phthalate results in increased expression of FABP4 mRNA] |
CTD |
PMID:25543134 PMID:25777084 PMID:27384973 PMID:35421560 |
|
NCBI chr 2:91,580,858...91,585,578
Ensembl chr 2:91,580,885...91,585,578
|
|
G |
Fads6 |
fatty acid desaturase 6 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of FADS6 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr10:100,522,981...100,538,181
Ensembl chr10:100,522,981...100,538,181
|
|
G |
Faim2 |
Fas apoptotic inhibitory molecule 2 |
decreases expression |
ISO |
mono-(2-ethylhexyl)phthalate results in decreased expression of FAIM2 mRNA |
CTD |
PMID:22401849 |
|
NCBI chr 7:130,632,368...130,659,353
Ensembl chr 7:130,633,348...130,659,168
|
|